EXHIBIT 29

[redacted]

PART 5

PATENT APPLICATION FEE DETERMINATION RECORD

Substitute for Form PTO-875

Application or Docket Number: 15/705,172

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	70		N/A	
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A	300		N/A	
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	360		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	2 minus 20 =	*	x 40 =	0.00	OR		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	2 minus 3 =	*	x 210 =	0.00			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				0.00			
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	730		TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with 37 CFR § 1.6(a)(4).

Dated: September 26, 2017
Electronic Signature for Amy E. Mandragouras, Esq.: /Amy E. Mandragouras, Esq./

Docket No.: AVN-008CN41
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen Donald Wilton *et al.*

Application No.: 15/705,172 Confirmation No.: 2879

Filed: September 14, 2017 Art Unit: 1674

For: ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF Examiner: K. Chong

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In compliance with 37 C.F.R. § 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the document listed on the attached PTO/SB/08. In accordance with 37 C.F.R. § 1.98(a)(2)(i)-(iv), Applicant has not included a copy of the U.S. Patent Publication.

It is respectfully requested that the document listed on the PTO/SB/08 be expressly considered by the Examiner during the prosecution of this application, and that the document be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The filing of this Information Disclosure Statement is not to be interpreted as a representation that the cited document is material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of the document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant understands the Examiner will make an independent evaluation of the cited document.

Application No.: 15/705,172 Docket No.: AVN-008CN41

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 C.F.R. § 1.97(b)(1)). Applicant believes no fee is due with this statement.

Dated: September 26, 2017

Respectfully submitted,

Electronic signature: /Amy E. Mandragouras, Esq./
Amy E. Mandragouras, Esq.
Registration No.: 36,207
NELSON MULLINS RILEY & SCARBOROUGH LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 217-4626
(617) 217-4699 (Fax)
Attorney/Agent For Applicant

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	K. Chong
Attorney Docket Number	AVN-008CN41

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20170009234	A1	2017-01-12	WILTON et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	K. Chong
Attorney Docket Number	AVN-008CN41

	1	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	K. Chong
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-26
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	30470917
Application Number:	15705172
International Application Number:	
Confirmation Number:	2879
Title of Invention:	ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
First Named Inventor/Applicant Name:	Stephen Donald WILTON
Customer Number:	123147
Filer:	Amy E. Mandragouras/Anita Costa
Filer Authorized By:	Amy E. Mandragouras
Attorney Docket Number:	AVN-008CN41
Receipt Date:	26-SEP-2017
Filing Date:	14-SEP-2017
Time Stamp:	17:31:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	2017-00-26_IDSTRANS_AVN-008CN41_4837-0227-6945_v1.pdf	24722 a2f4b83aa8b4579bae0fe7b868490637ee44a3f7	no	2

Warnings:

Information:					
This is not an USPTO supplied IDS fillable form					
2	Information Disclosure Statement (IDS) Form (SB08)	SB08.pdf	1058268 720550c02315856293e36d5f694fb7618ea25b9a	no	4
Warnings:					
Information:					
			Total Files Size (in bytes):	1082990	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

To: chris.schlauch@nelsonmullins.com,ipqualityassuranceboston@nelsonmullins.com,ipboston.docketing@nel
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 123147

Sep 26, 2017 03:40:05 AM

Dear PAIR Customer:

Nelson Mullins Riley & Scarborough LLP/Sarepta
One Post Office Square
Boston, MA 02109
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 123147 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:
The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
15705172	APP.FILE.REC	09/26/2017	AVN-008CN41

To view your correspondence online or update your email addresses, please visit us anytime at https://sportal.uspto.gov/secure/myportal/privatepair.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/705,172	09/14/2017	Stephen Donald WILTON	AVN-008CN41	2879

123147 7590 10/05/2017

Nelson Mullins Riley & Scarborough LLP/Sarepta
One Post Office Square
Boston, MA 02109

EXAMINER
CHONG, KIMBERLY

ART UNIT	PAPER NUMBER
1674	

NOTIFICATION DATE	DELIVERY MODE
10/05/2017	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ipboston.docketing@nelsonmullins.com
chris.schlauch@nelsonmullins.com
ipqualityassuranceboston@nelsonmullins.com

Office Action Summary	Application No. 15/705,172	Applicant(s) WILTON ET AL.	
	Examiner KIMBERLY CHONG	Art Unit 1674	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *09/26/2017*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *2 and 3* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☐ Claim(s) _____ is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☒ Claim(s) *2 and 3* are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *09/14/2017* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date *09/22/2017*.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

The present application is being examined under the pre-AIA first to invent provisions.

DETAILED ACTION

Status of Application/Amendment/Claims

Claims 2 and 3 are pending and currently under examination.

Information Disclosure Statement

The submission of the Information Disclosure Statements on 09/22/2017 is in compliance with 37 CFR 1.97. The information disclosure statement has been considered by the examiner and signed copies have been placed in the file.

Claim Rejections - 35 USC § 103

The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 2 and 3 are rejected under pre-AIA 35 U.S.C. 103(a) as being obvious over van Ommen (WO2004/083432 cited on IDS filed 09/22/2017) and Koenig et al. (Nature 338, 509 - 511 06 April 1989 cited on IDS filed 09/22/2017).

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

2. Ascertaining the differences between the prior art and the claims at issue.

3. Resolving the level of ordinary skill in the pertinent art.

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

The claims are drawn to an antisense oligonucleotide of 20-31 bases comprising a base sequence 100% complementary to consecutive bases of exon 53 of the human dystrophin pre-mRNA, wherein the antisense oligonucleotide base sequence comprises at least 12 consecutive bases of SEQ ID NO: 195, wherein uracil bases are thymine bases, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide, and wherein the antisense induces exon 53 skipping. The claims are further drawn to a pharmaceutical composition comprising said antisense oligonucleotide.

van Ommen teach a genus of oligonucleotides 16-50 complementary to exon 53 and has identified an active range in the DMD gene and have shown two oligonucleotide h53AON1 and h53AON2 that cause skipping of exon 53 (see Table 2). van Ommen et al. teach the oligonucleotides can be complementary to the exon in the pre-mRNA. Thus given the sequence of the DMD gene has been identified, as demonstrated by Koenig et al., an oligonucleotide sequence complementary to that

portion of the mRNA is exactly determined by the simple base pairing rules of DNA and RNA (G being complementary to C, and A being complementary to T (or U)).

vanOmmen et al. the oligonucleotide can have modifications such as morpholino phosphorodiamidate, peptide nucleic acid and locked nucleic acids, for example, and further teach the oligonucleotide comprises modified internucleoside linkages (see claim 12 and page 23). The oligonucleotide taught by van Ommen et al. encompasses both DNA and RNA nucleic acids as well as nucleic acids that are a combination of DNA and RNA as stated on page 9: lines 9-10 “Any oligonucleotide fulfilling the requirements of the invention may be used to induce exon skipping in the DMD gene." van Ommen et al. teach different nucleic acids may be used to generate the oligonucleotide (see page 9 line 30 - page 10). Thus oligonucleotides in which uracil bases are thymine bases are encompassed in the meaning of ‘oligonucleotide’ taught by van Ommen et al.

It would have been obvious to one of ordinary skill in the art to make an antisense oligonucleotide of 20-31 bases comprising at least 12 bases of SEQ ID No. 195. Given van Ommen et al. teach a genus of oligonucleotides of up to 50 nucleotides in length, one of skill in the art would have been motivated to use the sequence of h53AON1 to arrive at oligonucleotides of 20 nucleotides and having 12 nucleotides of SEQ ID No. 195 (which overlaps with 3 nucleotides of h53AON1). Because van Ommen et al. has identified exon 53 and shown oligonucleotides targeting this region can cause exon skipping and because the mRNA sequence containing the exon 53 was known in the prior art, as shown by Keonig et al., the combination of these teachings

provides motivation to prepare obvious variants of h53AON1 to try and optimize the activity of the oligonucleotide to prepare the most effective therapeutic for treating DMD.

It would have been routine and a common strategy to try and enhance the oligonucleotide by identifying variants of that oligonucleotide that have a higher level of activity and a common and efficient strategy for doing so is to synthesize and test longer oligonucleotides containing within them the sequence known to have the desired activity.

Thus in the absence of evidence to the contrary, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington,* 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP §

717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/forms/. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

Claims 2 and 3 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-36 of U.S. Patent No. 8,455,636. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the patent are drawn to antisense oligonucleotides having at least 17 consecutive bases of SEQ ID No. 193.

Claims 2 and 3 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 8,232,384. Although the conflicting claims are not identical, they are not patentably

distinct from each other because the instant claims and the claims of the patent are drawn to antisense oligonucleotides having at least 17 consecutive bases of SEQ ID No. 193.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a).

706.07(a) Final Rejection, When Proper on Second Action [R-07.2015]

Second or any subsequent actions on the merits shall be final, except where the examiner introduces a new ground of rejection that is neither necessitated by applicant's amendment of the claims, nor based on information submitted in an information disclosure statement filed during the period set forth in 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p). Where information is submitted in an information disclosure statement during the period set forth in 37 CFR 1.97(c) with a fee, the examiner may use the information submitted, e.g., a printed publication or evidence of public use, and make the next Office action final whether or not the claims have been amended, provided that no other new ground of rejection which was not necessitated by amendment to the claims is introduced by the examiner. See MPEP § 609.04(b).

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Kimberly Chong whose telephone number is 571-272-3111.** The examiner can normally be reached Monday thru Friday 9-5 pm.

If attempts to reach the examiner by telephone are unsuccessful please contact the SPE for 1674 Ram Shukla at 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file

folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Kimberly Chong/
Primary Examiner
Art Unit 1674

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/857,555	09/17/2015	Stephen Donald Wilton	AVN-008CN31	6627

123147 7590 11/06/2015

Nelson Mullins Riley & Scarborough LLP/Sarepta
One Post Office Square
Boston, MA 02109

EXAMINER
CHONG, KIMBERLY

ART UNIT	PAPER NUMBER
1674	

NOTIFICATION DATE	DELIVERY MODE
11/06/2015	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ipboston.docketing@nelsonmullins.com
chris.schlauch@nelsonmullins.com
ipqualityassuranceboston@nelsonmullins.com

Office Action Summary	Application No. 14/857,555	Applicant(s) WILTON ET AL.	
	Examiner KIMBERLY CHONG	Art Unit 1674	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *09/21/2015*.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5)☒ Claim(s) *21-24* is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6)☐ Claim(s) _____ is/are allowed.

7)☒ Claim(s) *21-24* is/are rejected.

8)☐ Claim(s) _____ is/are objected to.

9)☐ Claim(s) _____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☒ The drawing(s) filed on *09/17/2015* is/are: a)☒ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☒ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☒ Certified copies of the priority documents have been received in Application No. 11/570,691.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☒ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date *9/18/15,9/21/15,10/15/15*.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .

4) ☐ Other: _____.

The present application is being examined under the pre-AIA first to invent provisions.

DETAILED ACTION

Status of Application

Claims 21-24 are pending and currently under examination. SEQ ID No. 207 is free of the prior art searched.

Information Disclosure Statement

The submission of the Information Disclosure Statements on 09/18/2015, 09/21/2015 and 10/15/2015 is in compliance with 37 CFR 1.97. The information disclosure statements have been considered by the examiner and signed copies have been placed in the file.

The information disclosure statements filed on 09/18/2015 having 8 pages fails to comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609 because of the following reasons: The NPL documents having numbers 12 and 13 contained in the information disclosure statement filed 09/18/2015 have not been considered because the documents do not have the required date listed. The remaining documents have been considered and a signed copy has been placed in the file.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225

USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington,* 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 21-22 of Application No. 14/857,561. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the patent are drawn to patently indistinguishable subject matter.

Claims 21 and 22 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-69 of U.S. Patent No. 8,524,880. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the patent are drawn to patently indistinguishable subject matter.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Kimberly Chong** whose telephone number is **571-272-3111**. The examiner can normally be reached Monday thru Friday between 9-5 pm.

If attempts to reach the examiner by telephone are unsuccessful please contact the SPE for 1674 Mark Shibuya at 571-272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see http://pair-direct.uspto.gov.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Kimberly Chong/
Primary Examiner
Art Unit 1674

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with 37 CFR § 1.6(a)(4).

Dated: September 22, 2017
Electronic Signature for Amy E. Mandragouras, Esq.: /Amy E. Mandragouras, Esq./

Docket No.: AVN-008CN41
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen Donald Wilton *et al.*

Application No.: 15/705,172 Confirmation No.: 2879

Filed: September 14, 2017 Art Unit: 1674

For: ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the documents listed on the PTO/SB/08 be expressly considered by the Examiner during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

For the Examiner's convenience in reviewing this continuation application, Applicant submits a consolidated PTO/SB/08, listing all references cited during the prosecution of the parent applications. The present application is a continuation of U.S. Application No. 15/274,772, filed September 23, 2016 (Atty. Docket No. AVN-008CN37). In accordance with 37 C.F.R. §1.98(d), copies of the references previously cited by or submitted to the Office in the parent applications are not enclosed, but will be provided upon request.

Applicant calls to the attention of the Examiner the following Applications and Office Actions issued therein:

Applications				
Examiner's Initials	*Serial No.*	*Filing Date*	*First Named Inventor*	*Docket No.*
	11/570,691	January 15, 2008	Stephen Donald Wilton	AVN-008
	12/837,356	July 15, 2010	Stephen Donald Wilton	AVN-008CN
	12/837,359	July 15, 2010	Stephen Donald Wilton	AVN-008CN2
	12/860,078	August 20, 2010	Stephen Donald Wilton	AVN-008CN3
	13/168,857	June 24, 2011	Stephen Donald Wilton	AVN-008CN4
	13/168,863	June 24, 2011	Stephen Donald Wilton	AVN-008CN5
	13/270,500	October 11, 2011	Stephen Donald Wilton	AVN-008CN6
	13/270,531	October 11, 2011	Stephen Donald Wilton	AVN-008CN7
	13/270,744	October 11, 2011	Stephen Donald Wilton	AVN-008CN8
	13/270,937	October 11, 2011	Stephen Donald Wilton	AVN-008CN9
	13/270,992	October 11, 2011	Stephen Donald Wilton	AVN-008CN10
	13/271,080	October 11, 2011	Stephen Donald Wilton	AVN-008CN11
	13/727,415	December 26, 2012	Stephen Donald Wilton	AVN-008CN12
	13/741,150	January 14, 2013	Stephen Donald Wilton	AVN-008CN13
	13/826,613	March 14, 2013	Stephen Donald Wilton	AVN-008CN14
	13/826,880	March 14, 2013	Stephen Donald Wilton	AVN-008CN15
	13/902,376	May 24, 2013	Stephen Donald Wilton	AVN-008CN17
	13/963,578	August 9, 2013	Stephen Donald Wilton	AVN-008CN18

	14/086,859	November 21, 2013	Stephen Donald Wilton	AVN-008CN19
	14/178,059	February 11, 2014	Stephen Donald Wilton	AVN-008CN20
	14/223,634	March 24, 2014	Stephen Donald Wilton	AVN-008CN22
	14/273,318	May 8, 2014	Stephen Donald Wilton	AVN-008CN23
	14/273,379	May 8, 2014	Stephen Donald Wilton	AVN-008CN24
	14/316,603	June 26, 2014	Stephen Donald Wilton	AVN-008CN25
	14/316,609	June 26, 2014	Stephen Donald Wilton	AVN-008CN26
	14/317,952	June 27, 2014	Stephen Donald Wilton	AVN-008CN27
	14/740,097	June 15, 2015	Stephen Donald Wilton	AVN-008CN28
	14/852,090	September 11, 2015	Stephen Donald Wilton	AVN-008CN29RCE
	14/852,149	September 11, 2015	Stephen Donald Wilton	AVN-008CN30
	14/857,555	September 17, 2015	Stephen Donald Wilton	AVN-008CN31
	14/857,561	September 17, 2015	Stephen Donald Wilton	AVN-008CN32RCE
	14/858,250	September 18, 2015	Stephen Donald Wilton	AVN-008CN33
	15/274,719	September 23, 2016	Stephen Donald Wilton	AVN-008CN36
	15/274,772	September 23, 2016	Stephen Donald Wilton	AVN-008CN37
	15/349,535	11-11-2016	Stephen Donald Wilton	AVN-008RE
	12/605,276	October 23, 2009	Peter SAZANI	AVN-009RCE
	13/829,545	March 14, 2013	Peter SAZANI	AVN-009CN
	13/830,253	March 14, 2013	Peter SAZANI	AVN-009CN2
	14/523,610	October 24, 2014	Peter SAZANI	AVN-009DV
	14/852,257	September 11, 2015	Peter SAZANI	AVN-009DVCN1RCE

	14/852,264	September 11, 2015	Peter SAZANI	AVN-009DVCN2
	14/857,569	September 17, 2015	Peter SAZANI	AVN-009DVCN3
	14/857,590	September 17, 2015	Peter SAZANI	AVN-009DVCN4
	14/858,416	September 18, 2015	Peter SAZANI	AVN-009DVCN5
	14/743,856	June 18, 2015	R.K. BESTWICK	AVN-10PCCN
	14/213,629	March 14, 2014	E.M. KAYE	AVN-012ARCE
	14/214,567	March 14, 2014	E.M. KAYE	AVN-012BRCE
	14/213,607	March 14, 2014	R.K. BESTWICK	AVN-013A
	14/214,480	March 14, 2014	R.K. BESTWICK	AVN-013BRCE
	14/942,629	November 16, 2015	R.K. BESTWICK	AVN-013ACN
	13/509,331	July 9, 2012	S.D. WILTON	AVN-015US
	14/108,137	December 16, 2013	S.D. WILTON	AVN-015USCN
	14/944,886	November 18, 2015	S.D. WILTON	AVN-015USCN2
	14/213,641	March 14, 2014	R.K. BESTWICK	AVN-017RCE
	14/776,533	September 14, 2015	R.K. BESTWICK	AVN-017CPUS

Office Actions (copies enclosed)			
Examiner's Initials	*Serial No.*	*Date Mailed from USPTO*	*Examiner*
	11/570,691	August 16, 2010	Kimberly Chong
	11/570,691	March 15, 2010	Kimberly Chong
	11/570,691	May 26, 2009	Kimberly Chong
	12/837,356	May 3, 2013	Kimberly Chong
	12/837,356	April 3, 2013	Kimberly Chong
	12/837,356	August 2, 2012	Kimberly Chong
	12/837,359	March 12, 2012	Kimberly Chong
	12/837,359	October 5, 2011	Kimberly Chong
	12/837,359	March 30, 2011	Kimberly Chong
	12/837,359	December 22, 2010	Kimberly Chong
	12/860,078	February 14, 2011	Kimberly Chong
	13/168,857	July 12, 2012	Kimberly Chong
	13/168,863	March 8, 2013	Kimberly Chong
	13/168,863	October 11, 2012	Kimberly Chong
	13/168,863	August 8, 2012	Kimberly Chong

	13/270,500	March 15, 2013	Kimberly Chong
	13/270,500	July 30, 2012	Kimberly Chong
	13/270,500	March 14, 2012	Kimberly Chong
	13/270,531	June 28, 2012	Kimberly Chong
	13/270,531	March 14, 2012	Kimberly Chong
	13/270,744	April 3, 2013	Kimberly Chong
	13/270,744	August 6, 2012	Kimberly Chong
	13/270,744	March 14, 2012	Kimberly Chong
	13/270,937	February 25, 2013	Kimberly Chong
	13/270,937	June 14, 2012	Kimberly Chong
	13/270,937	March 14, 2012	Kimberly Chong
	13/270,992	April 4, 2013	Kimberly Chong
	13/270,992	July 30, 2012	Kimberly Chong
	13/270,992	March 16, 2012	Kimberly Chong
	13/271,080	March 26, 2013	Kimberly Chong
	13/271,080	July 30, 2012	Kimberly Chong
	13/271,080	March 14, 2012	Kimberly Chong
	13/727,415	February 6, 2013	Kimberly Chong
	13/741,150	March 16, 2015	Kimberly Chong
	13/741,150	September 18, 2014	Kimberly Chong
	13/741,150	April 11, 2014	Kimberly Chong
	13/741,150	September 24, 2013	Kimberly Chong
	13/826,613	July 22, 2014	Kimberly Chong
	13/826,613	January 7, 2014	Kimberly Chong
	13/826,613	July 17, 2013	Kimberly Chong
	13/826,880	June 22, 2015	Kimberly Chong
	13/826,880	January 26, 2015	Kimberly Chong
	13/826,880	April 15, 2014	Kimberly Chong
	13/826,880	September 11, 2013	Kimberly Chong
	13/902,376	June 5, 2014	Kimberly Chong
	13/902,376	January 7, 2014	Kimberly Chong
	13/902,376	July 18, 2013	Kimberly Chong
	13/963,578	September 24, 2013	Kimberly Chong
	14/086,859	June 30, 2014	Kimberly Chong
	14/086,859	January 27, 2014	Kimberly Chong
	14/178,059	March 31, 2014	Kimberly Chong
	14/223,634	April 15, 2015	Kimberly Chong
	14/273,318	October 20, 2014	Kimberly Chong
	14/273,318	July 3, 2014	Kimberly Chong
	14/273,379	July 7, 2014	Kimberly Chong
	14/316,603	March 10, 2015	Kimberly Chong
	14/316,603	September 26, 2014	Kimberly Chong

	14/316,609	March 16, 2015	Kimberly Chong
	14/316,609	October 21, 2014	Kimberly Chong
	14/317,952	March 18, 2015	Kimberly Chong
	14/317,952	November 7, 2014	Kimberly Chong
	14/740,097	November 14, 2016	Kimberly Chong
	14/740,097	April 8, 2016	Kimberly Chong
	14/740,097	November 6, 2015	Kimberly Chong
	14/852,090	April 15, 2016	Kimberly Chong
	14/852,090	January 6, 2016	Kimberly Chong
	14/852,090	October 15, 2015	Kimberly Chong
	14/852,149	November 24, 2015	Kimberly Chong
	14/857,555	April 12, 2016	Kimberly Chong
	14/857,555	November 6, 2015	Kimberly Chong
	14/857,561	April 18, 2016	Kimberly Chong
	14/857,561	March 15, 2016	Kimberly Chong
	14/857,561	February 17, 2016	Kimberly Chong
	14/857,561	January 8, 2016	Kimberly Chong
	14/857,561	October 23, 2015	Kimberly Chong
	14/858,250	November 6, 2015	Kimberly Chong
	12/605,276	June 18, 2014	J. McDonald
	12/605,276	October 18, 2013	J. McDonald
	12/605,276	December 23, 2011	J. McDonald
	12/605,276	August 24, 2011	J. McDonald
	12/605,276	February 11, 2011	J. McDonald
	13/829,545	June 6, 2014	J. McDonald
	13/830,253	June 11, 2014	J. McDonald
	13/830,253	November 26, 2013	J. McDonald
	14/523,610	May 11, 2016	J. McDonald
	14/852,257	October 27, 2015	J. McDonald
	14/852,257	October 6, 2015	J. McDonald
	14/852,264	April 21, 2016	J. McDonald
	14/852,264	October 21, 2015	J. McDonald
	14/857,569	May 6, 2016	J. McDonald
	14/857,569	November 19, 2015	J. McDonald
	14/857,590	May 16, 2016	J. McDonald
	14/857,590	November 19, 2015	J. McDonald
	14/858,416	May 4, 2016	J. McDonald
	14/858,416	October 27, 2015	J. McDonald
	14/214,567	July 7, 2016	E. Poliakova-Georgan
	14/214,567	December 3, 2015	E. Poliakova-Georgan
	14/214,567	June 24, 2015	E. Poliakova-Georgan
	14/213,607	September 15, 2015	D.H. Shin

	14/213,607	April 1, 2015	D.H. Shin
	14/213,607	September 18, 2014	D.H. Shin
	14/214,480	August 2, 2016	D.H. Shin
	14/214,480	October 19, 2015	D.H. Shin
	14/214,480	April 17, 2015	D.H. Shin
	14/214,480	September 19, 2014	D.H. Shin
	14/942,629	August 16, 2016	D.H. Shin
	13/509,331	September 16, 2013	T.A. Vivlemore
	13/509,331	January 28, 2013	T.A. Vivlemore
	14/108,137	April 29, 2015	T.A. Vivlemore
	14/108,137	October 9, 2015	T.A. Vivlemore
	14/108,137	October 3, 2014	T.A. Vivlemore
	14/944,886	April 27, 2017	T.A. Vivlemore
	14/944,886	September 30, 2016	T.A. Vivlemore
	14/213,641	August 1, 2016	D.H. Shin
	14/213,641	October 16, 2015	D.H. Shin
	14/213,641	March 31, 2015	D.H. Shin
	14/213,641	September 18, 2014	D.H. Shin
	14/213,629	May 23, 2016	E. Poliakova-Georgan
	14/213,629	August 21, 2015	E. Poliakova-Georgan
	14/213,629	December 29, 2014	E. Poliakova-Georgan
	14/743,856	August 1, 2016	A. Hudson Bowman
	14/776,533	February 28, 2017	D. Shin
	14/776,533	August 3, 2016	D. Shin
	15/274,719	December 16, 2016	K. Chong
	15/274,772	December 30, 2016	K. Chong
	15/274,772	September 18, 2017	K. Chong

The Examiner is requested to review the file histories of these applications, including cited references, Office Actions, Responses, etc., and is asked to contact Applicant's Attorney if the Examiner would like the Applicant to supply copies of any or all of the information included in any of these applications. For any of these applications, if Applicant's Attorney is not contacted by the Examiner with such a request, then it will be concluded that the Examiner has reviewed or will review the file content of these applications.

Applicant respectfully requests that the Examiner initial the blank columns next to the cited Applications and Office Actions, to indicate that the information has been considered by the Examiner. Alternatively, Applicant requests that the Examiner insert the phrase, "All references

considered except where lined through," on each page of the Information Disclosure Statement, along with the Examiner's initials.

The filing of this Information Disclosure Statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any documents herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant understands the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 C.F.R. § 1.97(b)(1)). Applicant believes no fee is due with this statement.

Dated: September 22, 2017

Respectfully submitted,

Electronic signature: /Amy E. Mandragouras, Esq./
Amy E. Mandragouras, Esq.
Registration No.: 36,207
NELSON MULLINS RILEY & SCARBOROUGH LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 217-4626
(617) 217-4699 (Fax)
Attorney/Agent For Applicant

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS

Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	1	Laboratory Notebook Entry (Exon 51 Experiments): RT-PCR Analysis of 8036 Cells, Pages 2, Exhibit Number 1179 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	2	Laboratory Notebook Entry (Exon 51 Experiments): RT-PCR Analysis of KM155.C25 Cells, Pages 2, Exhibit Number 1178 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	3	Laboratory Notebook Entry (Exon 51 Experiments): Transfection of 8036 Cells, Pages 1, Exhibit Number 1172 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	4	Laboratory Notebook Entry (Exon 51 Experiments): Transfection of KM155.C25 Cells, Pages 1, Exhibit Number 1171 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	5	Laboratory Notebook Entry (Exon 53 Experiments): RT-PCR Analysis of KM155.C25 Cells, Pages 2, Exhibit Number 1180 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	6	Laboratory Notebook Entry (Exon 53 Experiments): RT-PCR Analysis of R1809 Cells, Pages 2, Exhibit Number 1181 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	7	Laboratory Notebook Entry (Exon 53 Experiments): Transfection of KM155.C25 Cells, Pages 1, Exhibit Number 1173 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	8	Laboratory Notebook Entry (Exon 53 Experiments): Transfection of R1809 Cells, Pages 1, Exhibit Number 1174 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	9	Claims from US Application No. 11/233,495, 6 pages, dated September 21, 2005 (Exhibit Number 2068 filed in Interferences 106008, 106013, 106007 on November 18, 2014)
	10	Laboratory Notebook Entry: General RNA recovery, Pages 2, Exhibit Number 1176 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	11	Laboratory Notebook Entry: Lab-on-a-Chip Analysis, Pages 3, Exhibit Number 1184 filed in Interferences 106,007 and 106,008 on February 16, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	12	Larsen et al., "Antisense properties of peptide nucleic acid," Biochim. Et Biophys. Acta, Vol. 1489, pp. 159-166 (1999), Exhibit Number 1190 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	13	Letter from the FDA to Sarepta Therapeutics, Inc., Re: ACCELERATED APPROVAL for the use of Exondys 51 (eteplirsen), FDA Reference ID: 3987286, dated September 19, 2016, 11 pages.
	14	Letter to the U.S. Food and Drug Administration, (Dr. Billy Dunn, M.D. Director Division of Neurology Products, Office of Drug Evaluation 1, Center for Drug Evaluation and Research), for The Peripheral and Central Nervous System Advisory Committee Meeting (AdComm) supporting approval of eteplirsen, dated February 24, 2016, 4 pages.
	15	Letter to the U.S. Food and Drug Administration, (Dr. Janet Woodcock, M.D. Director, CDER), from The Congress of The United States regarding Duchenne muscular dystrophy, dated February 17, 2016, 7 pages.
	16	List of Publications for Matthew J. A. Wood, M.D., D. PHIL., 11 pages, (Exhibit Number 2124 filed in interferences 106,007 and 106,008 on February 17, 2015.
	17	LIU, Hong-Xiang et al., "Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins," Genes & Development, Vol. 12:1998-2012 (1998)
	18	Lu et al, "Massive Idiosyncratic Exon Skipping Corrects the Nonsense Mutation in Dystrophic Mouse Muscle and Produces Functional Revertant Fibers by Clonal Expansion," THE JOURNAL OF CELL BIOLOGY, Vol. 148(5): 985-995, March 6, 2000 ("Lu et al.") (Exhibit Number 1082 filed in interferences 106008, 106007 on December 23, 2014)
	19	LU, Qi Long et al., "Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse," Nature Medicine, Vol. 9(8):1009-1014 (2003)
	20	LU, Qi-long et al., "What Can We Learn From Clinical Trials of Exon Skipping for DMD?" Molecular Therapy - Nucleic Acids, Vol. 3:e152, doi:10.1038/mtna.2014.6, 4 pages (2014)
	21	Lyophilisation of Oligonucleotides, Pages 2, Exhibit Number 1133 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	22	MANN, Christopher J. et al., "Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse," PNAS, Vol. 98(1):42-47 (2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	23	MANN, Christopher J. et al., "Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy," The Journal of Gene Medicine, Vol. 4:644-654 (2002)
	24	MANNINO, Raphael J. et al., "Liposome Mediated Gene Transfer," BioTechniques, Vol. 6(7):682-690 (1988)
	25	Manual of Patent Examining Procedure 2308.02 (6th ed., rev. 3, July 1997), (University of Western Australia Exhibit 2143, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-2).
	26	Manzur A, et al.,. "Glucocorticoid corticosteroids for Duchenne muscular dystrophy," Cochrane Database Syst Rev. 2004;(2):CD003725.
	27	MARSHALL, N.B. et al., "Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing," Journal of Immunological Methods, Vol. 325:114-126 (2007)
	28	Mathews et al., "Expanded Sequence Dependence of Thermodynamic Parameters Improves Prediction of RNA Secondary Structure," J. Mol. Biol. 288:911-940 (1999), (University of Western Australia Exhibit 2131, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-31).
	29	Mathews et al., "Expanded Sequence Dependence of Thermodynamic Parameters Improves Prediction of RNA Secondary Structure," J. Mol. Biol., Vol. 288, pp. 911-940 (1999), Exhibit Number 1212 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	30	MATSUO, Masafumi et al., "Exon Skipping during Splicing of Dystrophin mRNA Precursor due to an Intraexon Deletion in the Dystrophin Gene of Duchenne Muscular Dystrophy Kobe," J. Clin. Invest., Vol. 87:2127-2131 (1991)
	31	MATSUO, Masafumi et al., "Treatment of Duchenne Muscular Dystrophy with Oligonucleotides against an Exonic Splicing Enhancer Sequence," Basic Appl. Myol., Vol. 13(6):281-285 (2003)
	32	MATSUO, Masafumi, "Duchenne and Becker Muscular Dystrophy: From Gene Diagnosis to Molecular Therapy," IUBMB Life, Vol. 53:147-152 (2002)
	33	MATSUO, Masafumi, "Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy," Brain & Development, Vol. 18:167-172 (1996)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	34	MATTEUCCI, Mark, "Structural modifications toward improved antisense oligonucleotides," Perspectives in Drug Discovery and Design, Vol. 4:1-16 (1996)
	35	Mazzone E, et al. "Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study," Neurology 2011;77(3):250-6.
	36	MCCARVILLE, M. Beth et al., "Rhabdomyosarcoma in Pediatric Patients: The Good, the Bad, and the Unusual," AJR, Vol. 176:1563-1569 (2001) (Exhibit Number 1034 filed in interferences 106008, 106007 on November 18, 2014)
	37	MCCLOREY, G. et al., "Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD," Gene Therapy, Vol. 13:1373-1381 (2006)
	38	MCCLOREY, G. et al., "Induced dystrophin exon skipping in human muscle explants," Neuromuscular Disorders, Vol. 16:583-590 (2006)
	39	MCCLOREY, Graham et al., "Splicing intervention for Duchenne muscular dystrophy," Current Opinion in Pharmacology, Vol. 5:529-534 (2005)
	40	McDonald CM, et al., "Profiles of Neuromuscular Diseases, Duchenne muscular dystrophy," Am J Phys Med Rehabil 1995;74:S70-S92
	41	McDonald CM, et al., "The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy," Muscle Nerve 2010;41:500-10.
	42	McDonald CM, et al., "The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations," Muscle Nerve 2010;42: 966-74.
	43	Mendell JR et al., "Evidence-based path to newborn screening for Duchenne muscular Dystrophy," Ann Neurol 2012;71:304-13.
	44	Mendell JR, et al., "Dystrophin immunity revealed by gene therapy in Duchenne muscular dystrophy," N Engl J Med 2010;363:1429-37.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	45	Mendell JR, et al., "Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy," N Engl J Med 1989;320:1592-97.
	46	MENDELL, Jerry R. et al., "Eteplirsen for the Treatment of Duchenne Muscular Dystrophy," Ann. Neurol., Vol. 74:637-647 (2013) (Exhibit Number 2058 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	47	MENDELL, Jerry R. et al., "Eteplirsen in Duchenne Muscular Dystrophy (DMD): 144 Week Update on Six-Minute Walk Test (6MWT) and Safety," slideshow, presented at the 19th International Congress of the World Muscle Society, 17 pages (2014) (Exhibit Number 2059 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	48	MENDELL, Jerry R. et al., "Gene therapy for muscular dystrophy: Lessons learned and path forward," Neuroscience Letters, Vol. 527:90-99 (2012)
	49	Merlini L, et al., "Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up," Muscle Nerve 2012;45:796-802.
	50	Mfold illustrations for Exon 51 and Exon 53 with varying amounts of intron sequence, (University of Western Australia Exhibit 2132, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-2).

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS

Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	1	Sarepta Briefing Information for the April 25, 2016 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee, Eteplirsen Briefing Document, NDA 206488, 186 pages.
	2	Sarepta Presentation at Peripheral and Central Nervous System Drugs Advisory Committee, April 25, 2016, 133 pages
	3	Sarepta Press Release, Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy, April 25, 2016, 2 pages
	4	Sarepta Therapeutics Press Release, dated January 12, 2015, Exhibit Number 1119 filed in interferences 106,007 and 106,008 on February 17, 2015.
	5	Sarepta Therapeutics, Advisory Committee Briefing Materials: Available for Public Release, "Peripheral and Central Nervous System Drugs Advisory Committee," Eteplirsen Briefing Document Addendum, NDA 206488, pages 1-9, dated January 22, 2016.
	6	Sarepta Therapeutics, Advisory Committee Briefing Materials: Available for Public Release, "Peripheral and Central Nervous System Drugs Advisory Committee," Eteplirsen Briefing Document, NDA 206488, pages 1-166, dated January 22, 2016.
	7	Sarepta Therapeutics, Inc. News Release, "Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51," September 19, 2016, 2 pages.
	8	Sarepta, "AVI BioPharma Initiates Dosing in Phase 2 Study of Eteplirsen in Duchenne Muscular Dystrophy Patients," press release, 4 pages, dated August 15, 2011 (Exhibit Number 2082 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	9	Sarepta, "Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy," press release, 3 pages, dated January 15, 2014 (Exhibit Number 2034 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	10	Sarepta, "Sarepta Therapeutics Reports Long-Term Outcomes through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy," press release, http://investorrelations.sarepta.com/phoenix.zhtml?c=64231&p=irol-newsArticle&id=1946426, 4 pages, dated July 10, 2014
	11	Scully, Michele et al., "Review of Phase II and Phase III Clinical Trials for Duchenne Muscular Dystrophy", Expert Opinion on Orphan Drugs, Vol.1(1):33-46 (2013)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	12	Second Preliminary Amendment filed in US Application No. 13/550,210, 5 pages, dated January 3, 2013 (Exhibit Number 2062 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	13	Second Written Opinion for Application No. PCT/AU2010/001520, 7 pages, dated October 13, 2011
	14	Semi Quantitative Lab-on-Chip Analysis of Second PCR Product, Pages 1, Exhibit Number 1183 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	15	Sequence Listing - Serial No. 13/550,210, as filed July 16, 2012 (9 pages), Exhibit Number 1205 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	16	Sequence of Exon 46 of Dystrophin Gene, 1 page
	17	Sequence of Exon 51 of Dystrophin Gene, 1 page
	18	Shabanpoor et al., "Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy," Nucleic Acids Res., pp. 1-11 (December, 2014), Exhibit Number 1114 filed in interferences 106,007 and 106,008 on February 17, 2015.
	19	SHAPIRO, Marvin B. et al., "RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression," Nucleic Acids Research, Vol. 15(17):7155-7174 (1987)
	20	SHERRATT, Tim G. et al., "Exon Skipping and Translation in Patients with Frameshift Deletions in the Dystrophin Gene," Am. J. Hum. Genet., Vol. 53:1007-1015 (1993)
	21	SHIGA, Nobuyuki et al., "Disruption of the Splicing Enhancer Sequence within Exon 27 of the Dystrophin Gene by a Nonsense Mutation Induced Partial Skipping of the Exon and Is Responsible for Becker Muscular Dystrophy," J. Clin. Invest., Vol. 100(9):2204-2210 (1997)
	22	SHIMIZU, Miho et al., "Oligo(2'-O-methyl)ribonucleotides Effective probes for duplex DNA," FEBS Letters, Vol. 302 (2):155-158 (1992) (Exhibit Number 1035 filed in interferences 106008, 106007 on November 18, 2014)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	23	Siemens Healthcare Diagnostics, Inc. v. Enzo Life Sciences, Inc., 2013 WL 4411227, *11 [Parallel cite: U.S.D.C., D. Mass., Civil No. 10-40124-FDS], Decided Aug. 14, 2013 (12 pages); [Cited as: 2013 WL 4411227], Exhibit Number 1210 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	24	SIERAKOWSKA, Halina et al., "Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides," Proc. Natl. Acad. Sci. USA, Vol. 93:12840-12844 (1996)
	25	Sontheimer et al., "Metal ion catalysis during group II intron self-splicing: parallels with the spliceosome," Genes & Development, Vol. 13, pp. 1729-1741 (1999), Exhibit Number 1195 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	26	Sontheimer et al., "Three Novel Functional Variants of Human U5 Small Nuclear RNA," Vol. 12, No. 2, pp. 734-746 (Feb., 1992), Exhibit Number 1194 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	27	SONTHEIMER, Erik J. et al., "Metal ion catalysis during splicing of premessenger RNA," Nature, Vol. 388:801-805 (1997) (Exhibit Number 1036 filed in interferences 106008, 106007 on November 18, 2014)
	28	SONTHEIMER, Erik J. et al., "The U5 and U6 Small Nuclear RNAs as Active Site Components of the Spliceosome," Science, Vol. 262:1989-1997 (1993) (Exhibit Number 1058 filed in interferences 106008, 106007 on November 18, 2014)
	29	Standard Operating Procedure FPLC Desalting, Pages 6, Exhibit Number 1144 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	30	Stanton, Robert et al., "Chemical Modification Study of Antisense Gapmers", Nucleic Acid Therapeutics, Vol. 22(5): 344-359 (2012)
	31	Statement On A Nonproprietary Name Adopted By the USAN Council, ETEPLIRSEN, Chemical Structure, 2010, pages 1-5.
	32	STEIN, CA, "Delivery of antisense oligonucleotides to cells: a consideration of some of the barriers," Monographic supplement series: Oligos & Peptides - Chimica Oggi - Chemistry Today, Vol. 32(2):4-7 (2014) (Exhibit Number 2022 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	33	STEIN, Cy A. et al., "Therapeutic Oligonucleotides: The Road Not Taken," Clin. Cancer Res., Vol. 17(20):6369-6372 (2011) (Exhibit Number 2026 filed in interferences 106008, 106013, 106007 on November 18, 2014)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	34	STEIN, David et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and PHosphorothioate DNA," Antisense & Nucleic Acid Drug Development, Vol. 7:151-157 (1997)
	35	Strober JB, "Therapeutics in Duchenne muscular dystrophy," NeuroRX 2006; 3:225-34.
	36	Summary of Professional Experience (Dr. Erik J. Sontheimer), Pages 4, Exhibit Number 1223 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	37	SUMMERTON, James et al., "Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems," Antisense & Nucleic Acid Drug Development, Vol. 7:63-70 (1997)
	38	SUMMERTON, James et al., "Morpholino Antisense Oligomers: Design, Preparation, and Properties," Antisense & Nucleic Acid Drug Development, Vol. 7:187-195 (1997)
	39	SUMMERTON, James, "Morpholino antisense oligomers: the case for an Rnase H-independent structural type," Biochimica et Biophysica Acta, Vol. 1489:141-158 (1999) (Exhibit Number 1038 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	40	Supplementary European Search Report for Application No. 10829367.1, 8 pages, dated May 22, 2013
	41	Suter et al., "Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human Beta-thalassemic mutations," 8:13 HUMAN MOLECULAR GENETICS 2415-2423 (1999) (Exhibit Number 1083 filed in interferences 106008, 106007 on December 23, 2014)
	42	T HOEN, Peter A.C. et al., "Generation and Characterization of Transgenic Mice with the Full-length Human DMD Gene," The Journal of Biological Chemistry, Vol. 283(9):5899-5907 (2008) Exhibit Number 2030 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	43	Table 1: Primer and Product Details for Exon 51 and 53 Reports on AONs of 20 to 50 Nucleotides dd 07 JAN 2015, Pages 1, Exhibit Number 1177 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	44	Takeshima et al., "Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient," Brain & Dev., Vol. 23, pp. 788-790 (2001), Exhibit Number 1196 filed in Interferences 106,007 and 106,008 on February 17, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	45	TAKESHIMA, Yasuhiro et al., "Modulation of In Vitro Splicing of the Upstream Intron by Modifying an Intra-Exon Sequence Which Is Deleted from the Dystrophin Gene in Dystrophin Kobe," J. Clin. Invest., Vol. 95:515-520 (1995)
	46	TANAKA, Kenji et al., "Polypurine Sequences within a Downstream Exon Function as a Splicing Enhancer," Molecular and Cellular Biology, Vol. 14(2):1347-1354 (1994)
	47	Telios Pharms., Inc. v. Merck KgaA, No. 96-1307, 1998 WL 35272018 (S.D. Cal. Nov. 18, 1998), 11 pages (Exhibit Number 2153 filed in interference 106013 on October 29, 2015)
	48	THANH, Le Htiet et al., "Characterization of Revertant Muscle Fibers in Duchenne Muscular Dystrophy, Using Exon-Specific Monoclonal Antibodies against Dystrophin," Am. J. Hum. Genet., Vol. 56:725-731 (1995)
	49	The Regents of the University of California v. Dako North America, Inc., U.S.D.C., N.D. California, No. C05-03955 MHP, April 22, 2009 (2009 WL 1083446 (N.D.Cal.), Exhibit Number 1206 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	50	TIAN, Xiaobing et al., "Imaging Oncogene Expression," Ann. N.Y. Acad. Sci., Vol. 1002:165-188 (2003) (Exhibit Number 2029 filed in interferences 106008, 106013, 106007 on November 18, 2014)

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	1	Transcript of 2nd Deposition of Erik J. Sontheimer, Ph.D., dated March 12, 2015, (Academisch Ziekenhuis Leiden Exhibit 1231, filed April 3, 2015 in Interference 106007 and 106008, pages 1-185).
	2	Transcript of 2nd Deposition of Matthew J.A. Wood, M.D., D. Phil, dated March 5, 2015, (Academisch Ziekenhuis Leiden Exhibit 1230, filed April 3, 2015 in Interference 106007 and 106008, pages 1-117).
	3	Transcript of December 12, 2014 Teleconference with Administrative Patent Judge Schafer (rough draft) (previously filed in Int. No. 106,008 as Ex. 2114), Pages 28 Exhibit Number 1001 filed in Interference 106,013 on February 17, 2015.
	4	Transcript of the January 21, 2015 deposition of Erik Sontheimer, Ph.D., Patent Interference Nos. 106,007 and 106,008, 98 pages, dated January 21, 2015 (Exhibit Number 2122 filed in interferences 106,007 and 106,008 on February 17, 2015.
	5	Transcript of the March 11, 2015 deposition of Judith van Deutekom, Ph.D., (University of Western Australia Exhibit 2141, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-168).
	6	Transcript of the March 12, 2015 deposition of Erik J. Sontheimer, Ph.D., (University of Western Australia Exhibit 2142, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-183).
	7	Transcript of the March 5, 2015 deposition of Matthew J. A. Wood, M.D., D. PHIL., (University of Western Australia Exhibit 2146, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-115).
	8	Transfection of AON, Pages 1, Exhibit Number 1170 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	9	U.S. Food and Drug Administration Presentation at Peripheral and Central Nervous System Drugs Advisory Committee, April 25, 2016, 178 pages.
	10	U.S. Food and Drug Administration Statement, dated December 30, 2014 (2 pages), Exhibit Number 1204 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	11	U.S. Patent Application No. 12/198,007, as-filed August 25, 2008 ("the '007 Application") (Exhibit Number 1073 filed in Interferences 106008, 106007 on December 23, 2014)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	12	U.S. Patent Application No. 12/976,381, as-filed December 22, 2010 ("the '381 Application") (Exhibit Number 1074 filed in interferences 106008, 106007 on December 23, 2014)
	13	U.S. Patent Application Publication No. 2001/0056077 ("Matsuo") (Exhibit Number 1080 filed in interferences 106008, 106007 on December 23, 2014)
	14	U.S. Patent Application Publication No. 2002/0049173 ("Bennett et al.") (Exhibit Number 1081 filed in interferences 106008, 106007 on December 23, 2014)
	15	U.S. Patent No. 5,190,931 ("the '931 Patent") (Exhibit Number 1069 filed in interferences 106008, 106007 on December 23, 2014)
	16	U.S. Patent No. 7,001,761 (the "Xiao" Patent) (Exhibit Number 1070 filed in interferences 106008, 106007 on December 23, 2014)
	17	University of Western Australia Objections to Opposition Evidence, served on February 24, 2015 filed in Interference No. 106,007, Exhibit 2150, filed April 10, 2015 in Interference Nos. 106007 and 106008, pages 1-15.
	18	University of Western Australia Objections to Opposition Evidence, served on February 24, 2015, filed in Interference No. 106,008, Exhibit 2151, filed April 10, 2015, in Interference Nos. 106007and 106008, pages 1-15.
	19	University of Western Australia v. Academisch Ziekenhuis Leiden, Decision - Motions - 37 C.F.R. § 41.125(a), filed in Patent Interference No. 106008, September 20, 2016, pages 1-20 (Doc 480)
	20	University of Western Australia v. Academisch Ziekenhuis Leiden, Decision - Motions - 37 CFR § 41.125(a) (Substitute), filed in Patent Interference No. 106007, May 12, 2016, pages 1-53 (Doc 476)
	21	University of Western Australia v. Academisch Ziekenhuis Leiden, Judgment - Motions - 37 C.F.R. § 41.127 filed in Patent Interference No. 106008, September 20, 2016, pages 1-3 (Doc 481)
	22	University of Western Australia v. Academisch Ziekenhuis Leiden, Judgment - Motions - 37 CFR § 41.127, filed in Patent Interference No. 106007, April 29, 2016, pages 1-3 (Doc 474)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	23	European Response, Application No. 13160338.3, 4 pages, dated June 26, 2014 (Exhibit Number 2085 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	24	University of Western Australia v. Academisch Ziekenhuis Leiden, Redeclaration - 37 CFR 41.203(c), filed in Patent Interference No. 106007, April 29, 2016, pages 1-2 (Doc 473)
	25	University of Western Australia v. Academisch Ziekenhuis Leiden, Withdrawal and Reissue of Decision on Motions, filed in Patent Interference No. 106007, May 12, 2016, pages 1-2 (Doc 475)
	26	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits (as of Apr. 3, 2015), filed in Patent Interference No. 106,007, April 3, 2015, pages 1-18, (Doc 423).
	27	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits (as of Apr. 3, 2015), filed in Patent Interference No. 106,008, April 3, 2015, pages 1-18 (Doc 435).
	28	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 18 pages, Patent Interference No. 106,007, (Doc 391), dated February 17, 2015.
	29	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 18 pages, Patent Interference No. 106,008, (Doc 398), dated February 17, 2015.
	30	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden List of Exhibits, 3 pages, Patent Interference No. 106,013, (Doc 147), dated February 17, 2015.
	31	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Notice of Service of Supplemental Evidence, 3 pages, Patent Interference No. 106,007 (Doc 414), dated March 9, 2015.
	32	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Notice of Service of Supplemental Evidence, 3 pages, Patent Interference No. 106,008 (Doc 422), dated March 9, 2015.
	33	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1 (35 U.S.C. § 112(a)), 83 pages, Patent Interference No. 106,008, (Doc 400), dated February 17, 2015

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	34	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1 (35 U.S.C. § 112(a)), 93 pages, Patent Interference No. 106,007, (Doc 392), dated February 17, 2015
	35	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 1 (Standing Order ¶ 203.1 and 37 C.F.R. § 41.202(a) and (e)), 20 pages, Patent Interference No. 106,013, (Doc 148), dated February 17, 2015
	36	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 2 (Indefiniteness), 31 pages, Patent Interference No. 106,007, (Doc 396), dated February 17, 2015
	37	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 2 (Indefiniteness), 32 pages, Patent Interference No. 106,008, (Doc 401), dated February 17, 2015
	38	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 3 (35 U.S.C. §135(b)), 44 pages, Patent Interference No. 106,008, (Doc 397), dated February 17, 2015
	39	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Opposition 3 (Standing Order § 203.1 and 37 C.F.R. § 41.202(a) and (e)), 20 pages, Patent Interference No. 106,007, (Doc 389), dated February 17, 2015.
	40	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 1 (For Judgment that UWA'a Claims are Unpatentable Under 35 U.S.C. §§ 102 and 103), dated April 3, 2015, filed in Patent Interference No. 106008, pages 1-17 (Doc 431).
	41	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 1 (For Judgment that UWA's Claims are Unpatentable Under 35 U.S.C. §§ 102 and 103), dated April 3, 2015, filed in Patent Interference No. 106007, pages 1-17 (Doc 424).
	42	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 2 (To Deny the Benefit of AU 2004903474), dated April 3, 2015, filed in Patent Interference No. 106007, pages 1-11(Doc 425).
	43	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 2 (To Deny the Benefit of AU 2004903474), dated April 3, 2015, filed in Patent Interference No. 106008, pages 1-12 (Doc 432).
	44	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 3 (For Judgment of Unpatentability based on Myriad) dated April 3, 2015, filed in Patent Interference No. 106007, pages 1-12 (Doc 426).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	45	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 3 (For Judgment of Unpatentability based on Myriad) dated April 3, 2015, filed in Patent Interference No. 106008, pages 1-13 (Doc 433).
	46	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 4 (In Support of Responsive Motion 4 to Add Two New Claims) dated April 3, 2015, filed in Patent Interference No. 106007, pages 1-17 (Doc 427).
	47	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Reply 4 (In Support of Responsive Motion 4 to Add Two New Claims) dated April 3, 2015, filed in Patent Interference No. 106008, pages 1-17 (Doc 434).
	48	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Request For Oral Argument, filed in Patent Interference No. 106,007, April 10, 2015, pages 1-3 (Doc 454).
	49	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Request For Oral Argument, filed in Patent Interference No. 106,008, April 10, 2015, pages 1-3 (Doc 462).
	50	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden Responsive Motion 4 (To Add Two New Claims), 57 pages, Patent Interference No. 106,008, (Doc 245), dated December 23, 2014.

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	1	Valorization Memorandum published by the Dutch Federation of University Medical Centers in March 2009, (University of Western Australia Exhibit 2140, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-33).
	2	VAN DEUTEKOM et al., "Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells," HUMAN MOLECULAR GENETICS Vol. 10, No. 15: 1547-1554 (2001) (Exhibit Number 1084 filed in interferences 106008, 106007 on December 23, 2014)
	3	van Deutekom et al., "Local Dystrophin Restoration with Antisense Oligonucleotide PRO051," N. Engl. J. Med., Vol. 357, No. 26, pp. 2677-2686 (December, 2007), Exhibit Number 1213 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	4	VAN DEUTEKOM, Judith C. T. et al., "Advances in Duchenne Muscular Dystrophy Gene Therapy," Nature Reviews Genetics, Vol. 4(10):774-783 (2003)
	5	Van Ommen 2002 PCT (WO 02/24906 Al), 43 pages,(Exhibit Number 1071 filed in interferences 106008, 106007 on December 23, 2014)
	6	van Putten M, et al., "The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology. PLoS ONE 2012;7:e31937, 13 pages
	7	Van Vliet, Laura et al., "Assessment of the Feasibility of Exon 45-55 Multiexon Skipping for Duchenne Muscular Dystrophy", BMC Medical Genetics, Vol.9(1):105 (2008)
	8	VERMA, Sandeep et al., "Modified Oligonucleotides: Synthesis and Strategy for Users," Annu. Rev. Biochem., Vol. 67:99-134 (1998) (Exhibit Number 1040 filed in interferences 106008, 106007 on November 18, 2014)
	9	Vikase Corp. v. Am. Nat'l. Can Co., No. 93-7651, 1996 WL 377054 (N.D. Ill. July 1, 1996), 3 pages (Exhibit Number 2152 filed in interference 106013 on October 29, 2015)
	10	VOIT, Thomas et al., "Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory randomised, placebo-controlled phase 2 study," Lancet Neurol., Vol. 13:987-996 (2014) (Exhibit Number 2037 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	11	VOLLOCH, Vladimir et al., "Inhibition of Pre-mRNA Splicing by Antisense RNA in Vitro: Effect of RNA Containing Sequences Complementary to Exons," Biochemical and Biophysical Research Communications, Vol. 179 (3):1593-1599 (1991)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	12	Wahlestedt et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids," PNAS, Vol. 97, No. 10, pp. 5633-5638 (May, 2000), Exhibit Number 1201 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	13	Wang et al., "In Vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy," J. Gene Medicine, Vol. 12, pp. 354-364 (March, 2010), Exhibit Number 1115 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	14	WANG, Chen-Yen et al., "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse," Proc. Natl. Acad. Sci. USA, Vol. 84:7851-7855 (1987)
	15	WATAKABE, Akiya et al., "The role of exon sequences in splice site selection," Genes & Development, Vol. 7:407-418 (1993)
	16	Watanabe et al., "Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302)," Oligonucleotides, Vol. 16, pp. 169- 180 (2006), Exhibit Number 1197 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	17	WHO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN: List 115, "CASIMERSEN," vol. 30(2): 3 pages (2016)
	18	WHO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN: List 115, "Golodirsen," vol. 30(2): 3 pages (2016)
	19	WIJNAENDTS, L.C.D. et al., "Prognostic importance of DNA flow cytometric variables in rhabdomyosarcomas," J. Clin. Pathol., Vol. 46:948-952 (1993) (Exhibit Number 1041 filed in interferences 106008, 106007 on November 18, 2014)
	20	Wilton et al. (2007) "Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript," Molecular Therapy 15(7):1288-1296, 10 pages, (Exhibit Number 2121 filed in interferences 106,007 and 106,008 on February 17, 2015
	21	WILTON, Stephen D. et al., "Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: where are we now?" Neuromuscular Disorders, Vol. 15:399-402 (2005)
	22	WILTON, Stephen D. et al., "Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides," Neuromuscular Disorders, Vol. 9:330-338 (1999)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	23	WO 2002/24906 A1 of AZL, (University of Western Australia Exhibit 2134, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-43.)
	24	WO 2004/083432 (the published AZL PCT Application, "Van Ommen"), Pages 71, Exhibit Number 1003 filed in Interference 106,013 on February 17, 2015.
	25	WO 2013/112053 A1, (University of Western Australia Exhibit 2130, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-177).
	26	WOLFF, Jon A. et al., "Direct Gene Transfer into Mouse Muscle in Vivo," Science, Vol. 247(4949 Pt. 1):1465-1468 (1990)
	27	WONG, Marisa L. et al., "Real-time PCR for mRNA quantitation," BioTechniques, Vol. 39:75-85 (2005) (Exhibit Number 1066 filed in interferences 106008, 106007 on November 18, 2014)
	28	Wood, "Toward an Oligonucleotide Therapy for Duchenne Muscular Dystrophy: A Complex Development Challenge," Science Translational Medicine, Vol. 2, No. 25, pp. 1-6 (March, 2010), Exhibit Number 1116 filed in interferences 106,007 and 106,008 on February 17, 2015,Doc 335.
	29	Written Opinion for Application No. PCT/AU2010/001520, 6 pages, dated January 21, 2011
	30	WU, B. et al., "Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino," Gene Therapy, Vol. 17:132-140 (2010)
	31	WU, Bo et al., "Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer," PNAS, Vol. 105(39):14814-14819 (2008)
	32	WU, Bo et al., "Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense Drug Development," PLoS One, vol. 6(5):e19906, 11 pages (2011)
	33	WU, George Y. et al., "Receptor-mediated Gene Delivery and Expression in Vivo," The Journal of Biological Chemistry, Vol. 263(29):14621-14624 (1988)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	34	WU, George Y. et al., "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry, Vol. 262(10):4429-4432 (1987)
	35	Wyatt et al. "Site-specific cross-linking of mammalian U5 snRNP to the 5′ splice site before the first step of pre-mRNA splicing," Genes & Development, Vol. 6, pp. 2542-2553 (1992), Exhibit Number 1198 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	36	Yin et al., "A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice," Human Mol. Gen., Vol. 18, No. 22, pp. 4405-4414 (2009), Exhibit Number 1200 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	37	Yin et al., "Cell Penetrating peptide-conjugated antisense cardiac dystrophin expression and function," Human Mol. Gen., Vol. 17, No. 24, pp. 3909-3918 (2008), Exhibit Number 1199 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	38	Yin et al., "Functional Rescue of Dystrophin-deficient mdx Mice by a ChimericPeptide-PMO," Mol. Therapy, Vol. 18, No. 10, pp. 1822-1829 (October, 2010), Exhibit Number 1117 filed in interferences 106,007 and 106,008 on February 17, 2015.
	39	Yokota et al., "Efficacy of Systematic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs," American Neurological Assoc., Vol. 65, No. 6, pp. 667-676 (June, 2009), Exhibit Number 1214 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	40	Zoltek Corp. v. U.S., 95 Fed. Cl. 681 (2011), 23 pages, (Academisch Ziekenhuis Leiden Exhibit 1236, filed May 5, 2015 in Interference 106007 and 106008).
	41	European Search Report for Application No. 12162995.0, 11 pages, dated January 15, 2013
	42	HAREL-BELLAN, Annick et al., "Specific Inhibition of c-myc Protein Biosynthesis Using an Antisense Synthetic Deoxy-Oligonucleotide in Human T Lymphocytes," The Journal of Immunology, Vol. 140(7):2431-2435 (1988)
	43	HUDZIAK, Robert M. et al., "Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation," Antisense & Nucleic Acid Drug Development, Vol. 6:267-272 (1996)
	44	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden's List of Exhibits as of May 5, 2015, filed in Patent Interference No. 106,007, May 5, 2015, pages 1-18 (Doc 466).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	45	University of Western Australia v. Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden's List of Exhibits as of May 5, 2015, filed in Patent Interference No. 106,008, May 5, 2015, pages 1-18 (Doc 474).
	46	University of Western Australia v. Academisch Ziekenhuis Leiden, AZL Exhibit List, 10 pages, Patent Interference No. 106,008, dated December 23, 2014 (Doc 244)
	47	University of Western Australia v. Academisch Ziekenhuis Leiden, UWA Motion 3 Requesting an additional Interference between UWA U.S. Patent No. 8,455,636 and AZL USSN 14/248,279, 36 pages, Patent Interference No. 106,007, dated November 18, 2014 (Doc 212)

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4458066		1984-07-03	Caruthers et al.	
	2	5034506		1991-07-23	Summerton et al.	
	3	5138045		1992-08-11	Cook et al.	
	4	5142047		1992-08-25	Summerton et al.	
	5	5149797		1992-09-22	Pederson et al.	
	6	5166315		1992-11-24	Summerton et al.	
	7	5185444		1993-02-09	Summerton et al.	
	8	5190931		1993-03-02	Inouye	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	9	5217866		1993-06-08	Summerton et al.
	10	5506337		1996-04-09	Summerton et al.
	11	5521063		1996-05-28	Summerton et al.
	12	5627274		1997-05-06	Kole et al.
	13	5665593		1997-09-09	Kole et al.
	14	5698685		1997-12-16	Summerton et al.
	15	5801154		1998-09-01	Baracchini et al.
	16	5869252		1999-02-09	Bouma et al.
	17	5892023		1999-04-06	Pirotzky et al.
	18	5916808		1999-06-29	Kole et al.
	19	5976879		1999-11-02	Kole et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	20	6153436		2000-11-28	Hermonat et al.	
	21	6210892		2001-04-03	Bennett et al.	
	22	6312900		2001-11-06	Dean et al.	
	23	6391636		2002-05-21	Monia	
	24	6451991		2002-09-17	Martin et al.	
	25	6653466		2003-11-25	Matsuo	
	26	6653467		2003-11-25	Matsuo et al.	
	27	6656732		2003-12-02	Bennett et al.	
	28	6727355		2004-04-27	Matsuo et al.	
	29	6784291		2004-08-31	Iversen et al.	
	30	6806084		2004-10-19	Debs et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	31	7001761		2006-02-21	Xiao
	32	7070807		2006-07-04	Mixson
	33	7163695		2007-01-16	Mixson
	34	7250289		2007-07-31	Zhou
	35	7314750		2008-01-01	Zhou
	36	7468418		2008-12-23	Iversen et al.
	37	7534879		2009-05-19	van Deutekom
	38	7655785		2010-02-02	Bentwich
	39	7655788		2010-02-02	Khvorova et al.
	40	7807816		2010-10-05	Wilton et al.
	41	7902160		2011-03-08	Matsuo et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	42	7960541		2011-06-14	Wilton et al.	
	43	7973015		2011-07-05	van Ommen et al.	
	44	8084601		2011-12-27	Popplewell et al.	
	45	8232384		2012-07-31	Wilton et al.	
	46	8324371		2012-12-04	Popplewell et al.	
	47	8361979		2013-01-29	Aartsma-Rus et al.	
	48	8436163		2013-05-07	Iversen et al.	
	49	8450474		2013-05-28	Wilton et al.	
	50	8455634		2013-06-04	Wilton et al.	
	51	8455635		2013-06-04	Wilton et al.	
	52	8455636		2013-06-04	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	53	8461325		2013-06-11	Popplewell et al.
	54	8476423		2013-07-02	Wilton et al.
	55	8486907		2013-07-16	Wilton et al.
	56	8501703		2013-08-06	Bennett et al.
	57	8501704		2013-08-06	Mourich et al.
	58	8524676		2013-09-03	Stein et al.
	59	8524880		2013-09-03	Wilton et al.
	60	8536147		2013-09-17	Weller et al.
	61	8552172		2013-10-08	Popplewell et al.
	62	8592386		2013-11-26	Mourich et al.
	63	8618270		2013-12-31	Iversen et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	64	8624019		2014-01-07	Matsuo et al.	
	65	8637483		2014-01-28	Wilton et al.	
	66	8697858		2014-04-15	Iversen	
	67	8741863		2014-06-03	Moulton et al.	
	68	8759307		2014-06-24	Stein et al.	
	69	8759507		2014-06-24	Van Deutekom	
	70	8779128		2014-07-15	Hanson et al.	
	71	8785407		2014-07-22	Stein et al.	
	72	8785410		2014-07-22	Iversen et al.	
	73	8835402		2014-09-16	Kole et al.	
	74	8865883		2014-10-21	Sazani et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	75	8871918		2014-10-28	Sazani et al.	
	76	8877725		2014-11-04	Iversen et al.	
	77	8895722		2014-11-25	Iversen et al.	
	78	8906872		2014-12-09	Iversen et al.	
	79	9018368		2015-04-28	Wilton et al.	
	80	9024007		2015-05-05	Wilton et al.	
	81	9035040		2015-05-19	Wilton et al.	
	82	9175286		2015-11-03	Wilton et al.	
	83	9217148		2015-12-22	Bestwick et al.	
	84	9234198		2016-01-12	Sazani et al.	
	85	9249416		2016-02-02	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	86	9416361		2016-08-16	Iversen et al.	
	87	9422555		2016-08-23	Wilton et al.	
	88	9434948		2016-09-06	Sazani et al.	
	89	9441229		2016-09-13	Wilton et al.	
	90	9447415		2016-09-20	Wilton et al.	
	91	9447416		2016-09-20	Sazani et al.	
	92	9447417		2016-09-20	Sazani et al.	
	93	9453225		2016-09-27	Sazani et al.	
	94	9506058		2016-11-29	Kaye	
	95	9605262		2017-03-28	Wilton et al.	
	96	9228187		2016-01-05	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20010056077		2001-12-27	Matsuo	
	2	20020055481	A1	2002-05-09	Matsuo et al.	
	3	20020049173	A1	2002-04-25	Bennett et al.	
	4	20020110819	A1	2002-08-15	Weller et al.	
	5	20020156235	A1	2002-10-24	Manoharan et al.	
	6	20030166588	A1	2003-09-04	Iversen et al.	
	7	20030224353	A1	2003-12-04	Stein et al.	
	8	20030235845	A1	2003-12-25	van Ommen et al.	
	9	20040266720	A1	2004-12-30	Iversen et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	10	20040248833	A1	2004-12-09	Emanuele et al.	
	11	20040254137	A1	2004-12-16	Ackermann et al.	
	12	20050026164	A1	2005-02-03	Zhou	
	13	20050048495	A1	2005-03-03	Baker et al.	
	14	20050153935	A1	2005-07-14	Iversen et al.	
	15	20060148740	A1	2006-07-06	Platenburg	
	16	20060099616	A1	2006-05-11	van Ommen et al.	
	17	20060147952	A1	2006-07-06	van Ommen et al.	
	18	20060287268	A1	2006-12-21	Iversen et al.	
	19	20070037165	A1	2007-02-15	Venter et al.	
	20	20070082861	A1	2007-04-12	Matsuo et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	21	20070265215	A1	2007-11-15	Iversen et al.	
	22	20080194463	A1	2008-08-14	Weller et al.	
	23	20080200409	A1	2008-08-21	Wilson et al.	
	24	20080209581	A1	2008-08-28	van Ommen et al.	
	25	20090076246	A1	2009-03-19	van Deutekom	
	26	20090082547	A1	2009-03-26	Iversen et al.	
	27	20090088562	A1	2009-04-02	Weller et al.	
	28	20090099066	A1	2009-04-16	Moulton et al.	
	29	20090228998	A1	2009-09-10	van Ommen et al.	
	30	20090269755	A1	2009-10-29	Aartsma-Rus et al.	
	31	20090312532	A1	2009-12-17	Van Deutekom et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	32	20100016215	A1	2010-01-21	Moulton et al.	
	33	20100130591	A1	2010-05-27	Sazani et al.	
	34	20100168212	A1	2010-07-01	POPPLEWELL et al.	
	35	20110015253	A1	2011-01-20	Wilton et al.	
	36	20110015258	A1	2011-01-20	Wilton et al.	
	37	20110046360	A1	2011-02-24	MATSUO et al.	
	38	20110110960	A1	2011-05-12	PLATENBURG	
	39	20110263682	A1	2011-10-27	De Kimpe et al.	
	40	20110263686	A1	2011-10-27	WILTON et al.	
	41	20110281787	A1	2011-11-17	Lu et al.	
	42	20110294753	A1	2011-12-01	De Kimpe et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	43	20110312086	A1	2011-12-22	Van Deutekom	
	44	20120053228	A1	2012-03-01	Iversen et al.	
	45	20120065244	A1	2012-03-15	Popplewell et al.	
	46	20120289457	A1	2012-11-15	Hanson	
	47	20120022134	A1	2012-01-26	DE KIMPE et al.	
	48	20120022144	A1	2012-01-26	Wilton et al.	
	49	20120022145	A1	2012-01-26	Wilton et al.	
	50	20120029057	A1	2012-02-02	Wilton et al.	
	51	20120029058	A1	2012-02-02	Wilton et al.	
	52	20120029059	A1	2012-02-02	Wilton et al.	
	53	20120029060	A1	2012-02-02	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	54	20120041050	A1	2012-02-16	Wilton et al.	
	55	20120046342	A1	2012-02-23	Van Deutekom et al.	
	56	20120059042	A1	2012-03-08	Platenburg et al.	
	57	20120065169	A1	2012-03-15	Hanson et al.	
	58	20120108652	A1	2012-05-03	POPPLEWELL et al.	
	59	20120108653	A1	2012-05-03	POPPLEWELL et al.	
	60	20120115150	A1	2012-05-10	Bozzoni et al.	
	61	20120122801	A1	2012-05-17	PLATENBURG	
	62	20120149756	A1	2012-06-14	Schumperli et al.	
	63	20120172415	A1	2012-07-05	Voit et al.	
	64	20120202752	A1	2012-08-09	Lu	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	65	20130116310	A1	2013-05-09	Wilton et al.	
	66	20130190390	A1	2013-07-25	SAZANI et al.	
	67	20130217755	A1	2013-08-22	WILTON et al.	
	68	20130253033	A1	2013-09-26	WILTON et al.	
	69	20130253180	A1	2013-09-26	WILTON et al.	
	70	20130274313	A1	2013-10-17	WILTON et al.	
	71	20130331438	A1	2013-12-12	WILTON et al.	
	72	20130072671	A1	2013-03-21	Van Deutekom	
	73	20130090465	A1	2013-04-11	MATSUO et al.	
	74	20130197220	A1	2013-08-01	Ueda	
	75	20130211062	A1	2013-08-15	Watanabe et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	76	20130289096	A1	2013-10-31	POPPLEWELL et al.	
	77	20130302806	A1	2013-11-14	Van Deutekom	
	78	20140080896	A1	2014-03-20	Nelson et al.	
	79	20140080898	A1	2014-03-20	Wilton et al.	
	80	20140094500	A1	2014-04-03	SAZANI et al.	
	81	20140155587	A1	2014-06-05	WILTON et al.	
	82	20140243515	A1	2014-08-28	WILTON et al.	
	83	20140243516	A1	2014-08-28	WILTON et al.	
	84	20140296323		2014-10-02	Leumann et al.	
	85	20140315862	A1	2014-10-23	Kaye	
	86	20140315977	A1	2014-10-23	BESTWICK et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	87	20140316123		2014-10-23	Matsuo et al.	
	88	20140323544	A1	2014-10-30	BESTWICK et al.	
	89	20140329762	A1	2014-11-06	KAYE	
	90	20140329881	A1	2014-11-06	Bestwick et al.	
	91	20140343266	A1	2014-11-20	Watanabe et al.	
	92	20140350067	A1	2014-11-27	Wilton et al.	
	93	20140350076		2014-11-27	van Deutekom	
	94	20140357698		2014-12-04	Van DEUTEKOM et al.	
	95	20140357855	A1	2014-12-04	Van DEUTEKOM et al.	
	96	20140057964	A1	2014-02-27	POPPLEWELL et al.	
	97	20140113955	A1	2014-04-24	De Kimpe et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	98	20140128592	A1	2014-05-08	De Kimpe et al.	
	99	20140213635	A1	2014-07-31	Van DEUTEKOM	
	100	20140221458	A1	2014-08-07	De Kimpe et al.	
	101	20140275212	A1	2014-09-18	van Deutekom	
	102	20150232839	A1	2015-08-20	Iversen et al.	
	103	20150376615	A1	2015-12-31	Wilton et al.	
	104	20150376616	A1	2015-12-31	Wilton et al.	
	105	20150376617	A1	2015-12-31	SAZANI et al.	
	106	20150376618	A1	2015-12-31	Sazani et al.	
	107	20150152415	A1	2015-06-04	SAZANI et al.	
	108	20150353931	A1	2015-12-10	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	109	20150361428	A1	2015-12-17	Bestwick et al.	
	110	20150045413	A1	2015-02-12	De Visser et al.	
	111	20150057330	A1	2015-02-26	Wilton et al.	
	112	20160002631	A1	2016-01-07	Wilton et al.	
	113	20160002632	A1	2016-01-07	Wilton et al.	
	114	20160002633	A1	2016-01-07	Sazani et al.	
	115	20160002634	A1	2016-01-07	Sazani et al.	
	116	20160002635	A1	2016-01-07	Wilton et al.	
	117	20160002637	A1	2016-01-07	Sazani et al.	
	118	20160040162	A1	2016-02-11	BESTWICK et al.	
	119	20160177301	A1	2016-06-23	Wilton et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	120	20160298111	A1	2016-10-13	Bestwick et al.	
	121	20170009233	A1	2017-01-12	WILTON et al.	
	122	20140045916	A1	2014-02-13	Iversen et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	2003284638	AU	A1	2004-06-18	KOBE UNIVERSITY		
	2	780517	AU	B2	2005-03-24	JCR Pharmaceuticals Co., Ltd.		
	3	2507125	CA	A1	2004-06-10	Masafumi Matsuo		
	4	1054058	EP	A1	2000-11-22	JCR Pharmaceuticals Co., Ltd.		
	5	1160318	EP	A2	2001-12-05	JCR Pharmaceuticals Co., Ltd		
	6	1160318	EP	B1	2008-05-28	Jcr Pharmaceuticals Co., Ltd		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	7	1191097	EP	A1	2002-03-27	LEIDS UNIVERSITAIR MEDISCH CENTRUM		
	8	1191098	EP	A2	2002-03-27	JCR PHARMACEUTICALS CO., LTD.		
	9	1191098	EP	B9	2006-06-28	Jcr Pharmaceuticals Co., Ltd		
	10	1495769	EP	A1	2005-01-12	LBR MEDBIOTECH B.V.		
	11	1495769	EP	B1	2008-02-27	Lbr Medbiotech B V		
	12	1544297	EP	A2	2005-06-22	Jcr Pharmaceuticals Co., Ltd		
	13	1544297	EP	B1	2009-09-16	Jcr Pharmaceuticals Co., Ltd		
	14	1568769	EP	A1	2005-08-31	MATSUO, MASAFUMI ET AL.		
	15	1606407	EP	B1	2013-12-18	ACADEMISCH ZIEKENHUIS LEIDEN		
	16	1619249	EP	B1	2008-09-24	Academisch Ziekenhuis Leiden		
	17	1619249	EP	A1	2006-01-25	ACADEMISCH ZIEKENHUIS LEIDEN		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	18	1766010	EP	B1	2007-03-28	Univ Western Australia		
	19	1857548	EP	A1	2007-11-21	Academisch Ziekenhuis Leiden		
	20	2119783	EP	A1	2009-11-18	PROSENSA TECHNOLOGIES B.V.		
	21	2135948	EP	B1	2014-09-17	Matsuo, Masafumi		
	22	2135948	EP	A2	2009-12-23	Matsuo, Masafumi		
	23	2206781	EP	A2	2010-07-14	The University of Western Australia		
	24	2258863	EP	A1	2010-12-08	UNIVERSITA 'DEGLI STUDI DI ROMA "LA SAPIENZA"		
	25	2284264	EP	A1	2011-02-16	Academisch Ziekenhuis Leiden		
	26	2374885	EP	A2	2011-10-12	Matsuo, Masafumi et al.		
	27	2386636	EP	A2	2011-11-16	Matsuo, Masafumi et al.		
	28	2392660	EP	A2	2011-12-07	Matsuo, Masafumi et al.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	29	2435582	EP	B1	2013-10-23	UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA		
	30	2435583	EP	B1	2014-07-09	UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA		
	31	2488165	EP	B1	2014-07-23	Universita Degli Studi di Ferrara		
	32	2500430	EP	A2	2012-09-19	Univ Western Australia		
	33	2530153	EP	A1	2012-12-05	Matsuo, Masafumi et al.		
	34	2530154	EP	A1	2012-12-05	Matsuo, Masafumi et al.		
	35	2530155	EP	A1	2012-12-05	MATSUO, MASAFUMI ET AL.		
	36	2530156	EP	A1	2012-12-05	MATSUO, MASAFUMI ET AL.		
	37	2581448	EP	A1	2013-04-17	ASSOCIATION INSTITUT DE MYOLOGIE ET AL.		
	38	2594640	EP	A1	2013-05-22	ACADEMISCH ZIEKENHUIS LEIDEN		
	39	2594641	EP	A1	2013-05-22	ACADEMISCH ZIEKENHUIS LEIDEN		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	40	2594642	EP	A1	2013-05-22	ACADEMISCH ZIEKENHUIS LEIDEN		
	41	2602322	EP	A1	2013-06-12	ACADEMISCH ZIEKENHUIS LEIDEN		
	42	2607484	EP	A1	2013-06-26	Prosensa Technologies B.V. et al.		
	43	2612917	EP	A1	2013-07-10	NIPPON SHINYAKU CO., LTD.		
	44	2614827	EP	A2	2013-07-17	ACADEMISCH ZIEKENHUIS LEIDEN		
	45	2623507	EP	A1	2013-08-07	NIPPON SHINYAKU CO., LTD.		
	46	2636740	EP	A1	2013-09-11	Academisch Ziekenhuis Leiden		
	47	2636741	EP	A1	2013-09-11	ACADEMISCH ZIEKENHUIS LEIDEN		
	48	2636742	EP	A1	2013-09-11	ACADEMISCH ZIEKENHUIS LEIDEN		
	49	2799548	EP	A1	2014-11-05	NIPPON SHINYAKU CO., LTD		
	50	2801618	EP	A1	2014-11-12	Academisch Ziekenhuis Leiden		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add]

NON-PATENT LITERATURE DOCUMENTS [Remove]

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	"Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients" ClinicalTrials.gov dated January 22, 2013	
	2	"Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients," Clinical Trial Identifier No. NCT01396239, ClinicalTrials.gov, dated July, 15, 2011, page 1-4.	
	3	"Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects with Duchenne Muscular Dystrophy," Clinical Trial Identifier No. NCT01540409, ClinicalTrials.gov, published online February 23, 2012, page 1-4.	
	4	"Eteplirsen - Inhibitor of Dystrophin Expression - Treatment of Duchenne Muscular Dystrophy", Drugs of the Future, Vol.38(1):13-17 (2013)	
	5	"Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US- 201," ClinicalTrials.gov dated July 31, 2012, 3 pages	
	6	"Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US- 201," ClinicalTrials.gov dated October 17, 2013, 3 pages	
	7	"Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US- 201," ClinicalTrials.gov dated February 27, 2012, 3 pages	
	8	2nd Expert Declaration of Dr. Erik Sontheimer ("2nd S Decl.") (Exhibit Number 1067 filed in interferences 106008, 106007 on December 23, 2014)	
	9	3rd Declaration of Erik J. Sontheimer, Ph.D. ("3rd S. Decl."), Pages 123, Exhibit Number 1186 filed in Interferences 106,007 and 106,008 on February 17, 2015.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	15705172
	Filing Date	2017-09-14
	First Named Inventor	Stephen Donald WILTON
	Art Unit	1674
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	AVN-008CN41

	10	A Comparative Study on AONs between 20 and 50 Nucleotides Designed to Induce the Skipping of Exon 53 from the Dystrophin Pre-mRNA, Pages 6, Exhibit Number 1128 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	11	A Comparative Study on AONs Between 20 and 50 Nucleotides Designed to Induce the Skipping of Exon 51 from the Dystrophin Pre-mRNA, Pages 6, Exhibit Number 1127 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	12	Aartsma-Rus A, et al. "Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations," Hum Mutat 2009;30:293-99.
	13	Aartsma-Rus et al., "Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy," BMC Medical Genetics 8:43 (2007), (University of Western Australia Exhibit 2135, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-9.)
	14	AARTSMA-RUS, Annemieke et al., "194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands," Neuromuscular Disorders, Vol. 23:934-944 (2013)
	15	AARTSMA-RUS, Annemieke et al., "Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense," Am. J. Hum. Genet., Vol. 74:83-92 (2004)
	16	AARTSMA-RUS, Annemieke et al., "Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Skipping: Indication for Steric Hindrance of SR Protein Binding Sites," Oligonucleotides, Vol. 15:284-297 (2005) (Exhibit Number 2016 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	17	AARTSMA-RUS, Annemieke et al., "Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms," Molecular Therapy, Vol. 17(3):548-553 (2009) (Exhibit Number 2014 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	18	AARTSMA-RUS, Annemieke et al., "Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms," Molecular Therapy, Vol. 17(3):548-553 (2009). Supplementary Table 1.
	19	AARTSMA-RUS, Annemieke et al., "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy," Neuromuscular Disorders, Vol. 12:S71-S77 (2002)
	20	AARTSMA-RUS, Annemieke et al., "Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients," Human Molecular Genetics, Vol. 12(8):907-914 (2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	21	ABBS, Stephen et al., "A convenient multiplex PCR system for the detection of dystrophin gene deletions: a comparative analysis with cDNA hybridisation shows mistypings by both methods," J. Med. Genet., Vol. 28:304-311 (1991)
	22	Abes, S. et al., "Efficient Splicing Correction by PNA Conjugation to an R6-Penetratin Delivery Peptide", Nucleic Acids Research Vol.35(13):4495-4502 (2007)
	23	AGRAWAL, Sudhir et al., "GEM 91 - An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS," Antisense Research and Development, Vol. 2:261-266 (1992)
	24	AGRAWAL, Sudhir et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," Proc. Natl. Acad. Sci. USA, Vol. 85:7079-7083 (1988)
	25	Ahmad A, et al., "Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy," Hum Mol Genet 2000;9:2507-2515.
	26	AKHTAR, Saghir et al., "Cellular uptake and intracellular fate of antisense oligonucleotides," Trends in Cell Biology, Vol. 2:139-144 (1992)
	27	AKHTAR, Saghir, "Delivery Strategies for Antisense Oligonucleotide Therapeutics," CRC Press, Inc., Boca Raton, FL, 160 pages (1995)
	28	Alignments of Dystrophin mRNA and Oligonucleotides, 6 pages, submitted to the Patent Trial and Appeal Board in Interference No. 106008, dated November 18, 2014 (Exhibit Number 1054 filed in interferences 106008, 106007 on November 18, 2014)
	29	ALTER, Julia et al., "Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology," Nature Medicine, Vol. 12(2):175-177 (2006)
	30	Amendment under 37 CFR 1.312 for Application No. 14/248,279, 5 pages, dated September 19, 2014 (Exhibit Number 2053 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	31	Analysis of Second PCR Product by Gel Electrophoresis, Pages 1, Exhibit Number 1182 filed in Interferences 106,007 and 106,008 on February 16, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	32	ANDERSON, W. French, "Human Gene Therapy," Science, Vol. 256:808-813 (1992)
	33	Annotated scenario introduced and referred to during March 12, 2015 deposition of Erik J. Sontheimer, Ph.D., (University of Western Australia Exhibit 2139, filed April 3, 2015 in Interferences 106007, 106008, and 106013, page 1.)
	34	ANTHONY, Karen et al., "Dystrophin quantification: Biological and Translational Research Implications," Neurology, Vol. 83:1-8 (2014) (Exhibit Number 2028 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	35	AON PS1958 Mass Spectrometry Data, Pages 7, Exhibit Number 1146 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	36	AON PS1958 UPLC Data, Pages 2, Exhibit Number 1157 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	37	AON PS1959 Mass Spectrometry Data, Pages 5, Exhibit Number 1147 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	38	AON PS1959 UPLC Data, Pages 2, Exhibit Number 1158 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	39	AON PS1960 Mass Spectrometry Data, Pages 8, Exhibit Number 1148 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	40	AON PS1960 UPLC Data, Pages 2, Exhibit Number 1159 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	41	AON PS1961 Mass Spectrometry Data, Pages 5, Exhibit Number 1149 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	42	AON PS1961 UPLC Data, Pages 2, Exhibit Number 1160 filed in Interferences 106,007 and 106,008 on February 16, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	43	AON PS1962 Mass Spectrometry Data, Pages 7, Exhibit Number 1150 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	44	AON PS1962 UPLC Data, Pages 2, Exhibit Number 1161 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	45	AON PS1963 Mass Spectrometry Data, Pages 10, Exhibit Number 1151 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	46	AON PS1963 UPLC Data, Pages 2, Exhibit Number 1162 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	47	AON PS1964 Mass Spectrometry Data, Pages 13, Exhibit Number 1152 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	48	AON PS1964 UPLC Data, Pages 2, Exhibit Number 1163 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	49	AON PS1965 Mass Spectrometry Data, Pages 9, Exhibit Number 1153 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	50	AON PS1965 UPLC Data, Pages 2, Exhibit Number 1164 filed in Interferences 106,007 and 106,008 on February 16, 2015.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc code: IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-15)
Approved for use through 07/31/2016. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	1	MITRPANT, Chalermchai et al., "Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping," Molecular Therapy, Vol. 17(8):1418-1426 (2009)
	2	MONACO, Anthony P. et al., "An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus," Genomics, Vol. 2:90-95 (1988)
	3	Morcos, Paul A., "Gene switching: analyzing a broad range of mutations using steric block antisense oligonucleotides," Methods in Enzymology, Vol. 313:174-189 (1999)
	4	MOULTON, H.M., "Compound and Method for Treating Myotonic Dystrophy," U.S. Application No. 12/493,140, 82 pages, filed June 26, 2009
	5	MOULTON, Hong M. et al., "Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy," Biochimica et Biophysica Acta, Vol. 1798:2296-2303 (2010)
	6	Muntoni F, et al., "Dystrophin and mutations: one gene, several proteins, multiple phenotypes," Lancet Neurol. 2003;2:731-40.
	7	MUNTONI, Francesco et al., "128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands," Neuromuscular Disorders, Vol. 15:450-457 (2005) (Exhibit Number 2025 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	8	MUNTONI, Francesco et al., "149th ENMC International Workshop and 1st TREAT-NMD Workshop on: 'Planning Phase I/II Clinical trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy,'" Neuromuscular Disorders, Vol. 18:268-275 (2008)
	9	Confirmatory Study of Eteplirsen in DMD Patients, An Open-Label, Multi-Center, 48-Week Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy, Clinical Trials.gov, Clinical Trial Identifier NCT02255552, May 26, 2015, 3 pages.
	10	NELSON, David L. et al., "Nucleotides and Nucleic Acids," Lehninger Principles of Biochemistry, 3rd Edition, Chapter 10, pages 325-328 and glossary page G-11, Worth Publishers, New York (2000)
	11	Nguyen TM, et. Al., "Use of Epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy," Am J Hum Genet 1993;52:1057-66.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	12	Oberbauer, "Renal uptake of an 18-mer phosphorothioate oligonucleotide," Kidney Int'l, Vol. 48, pp. 1226-1232 (1995), Exhibit Number 1191 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	13	Oligonucleotide Cleavage and Deprotection Laboratory Notebook Entry, Pages 1, Exhibit Number 1138 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	14	Oligonucleotide diagrams, 5 pages (Exhibit Number 1053 filed in interferences 106008, 106007 on November 18, 2014)
	15	Partial European Search Report for Application No. 10004274.6, 6 pages, dated October 2, 2012
	16	Partial European Search Report for Application No. 12162995.0, 6 pages, dated October 2, 2012
	17	Patentee's Response to European Patent Application No. 05076770.6, dated July 28, 2006, 4 pages
	18	Patrick O. Brown and Tidear D. Shalon v. Stephen P.A. Fodor, Dennis W. Solas and William J. Dower: Interference Merits Panel, Interference No. 104,358, 24 pages, dated August 9, 1999 (Exhibit Number 2113 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	19	PCT Application as-filed for application No. PCT/NL03/00214, 64 pages, dated September 21, 2005 (Exhibit Number 2042 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	20	PD-10 Desalting Columns, Pages 12, Exhibit Number 1141 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	21	Popplewell, et al., Design of Phosphorodiamidate Morpholino Oligomers (PMOs) For the Induction of Exon Skipping of the Human DMD Gene, DSGT Poster, 2008, 1 page.
	22	POPPLEWELL, Linda et al., "Design of phosphorodiamidate morpholino oligmers (PMOs) for the induction of exon skipping of the human DMD gene," Human Gene Therapy 19(10): ESGCT 2008 Poster Presentations, Page 1174, Poster No. P203

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	23	POPPLEWELL, Linda J. et al., "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials," Neuromuscular Disorders, Vol. 20(2):102-110 (2010) 9 pages (Exhibit Number 2031 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	24	POPPLEWELL, Linda J. et al., "Design of Antisense Oligonucleotides for Exon Skipping of the Human Dystrophin Gene," Human Gene Therapy 19(4): BSGT 2008 Poster Presentation, Page 407, Poster No. P-35
	25	POPPLEWELL, Linda J. et al., "Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene," Molecular Therapy, Vol. 17(3):554-561 (2009)
	26	POPPLEWELL, Linda J. et al., "Targeted Skipping of Exon 53 of the Human DMD Gene Recommendation of the Highly Efficient Antisense Oligonucleotide for Clinical Trial," Human Gene Therapy 20(4): BSGT 2009 Poster Presentations, Page 399, Poster No. P10
	27	Poster Abstract Listing for The Tenth Annual Meeting of the RNA Society, held at the Banff Centre for Conferences, in Banff, Alberta, Canada, from May 24-29, 2005, (University of Western Australia Exhibit 2137, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-11).
	28	Pramono, "Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence," Biochem. and Biophy. Res. Comm., Vol. 226, pp. 445-449 (1996), Exhibit Number 1192 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	29	Preliminary Amendment for Application No. 12/976,381, 4 pages, dated December 22, 2010 (Exhibit Number 2066 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	30	Preliminary Amendment for Application No. 12/198,007, 3 pages, dated November 7, 2008 (Exhibit Number 2067 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	31	Prescribing Information for EXONDYS 51 (eteplirsen) Injection, dated 09/2016, 10 pages
	32	Program Schedule for The Tenth Annual Meeting of the RNA Society, held at the Banff Centre for Conferences, in Banff, Alberta, Canada, from May 24-29, 2005, (University of Western Australia Exhibit 2136, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-4).
	33	Proliferation and Differentiation of Myoblast Cultures, Pages 2, Exhibit Number 1169 filed in Interferences 106,007 and 106,008 on February 16, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	34	Prosensa Press Release, dated October 10, 2014 (2 pages), Exhibit Number 1203 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	35	Prosensa, "GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy," press release, 4 pages, dated September 20, 2013 (Exhibit Number 2039 filed in Interferences 106008, 106013, 106007 on November 18, 2014)
	36	Raz et al. v. Davis et al., Board of Patent Appeals and Inteferences, Patent and Trademark Office, Int. No. 105,712, Tech. Ctr. 1600, September 29, 2011 (24 pages) (2011 WL 4568986 (Bd.Pat.App. & Interf.), Exhibit Number 1209 filed in Interferences 106,007 and 106,008 on February 17, 2015.
	37	REESE, Colin B. et al., "Reaction Between 1-Arenesulphonyl-3-Nitro-1,2,4-Triazoles and Nucleoside Base Residues. Elucidation of the Nature of Side-Reactions During Oligonucleotide Synthesis," Tetrahedron Letters, Vol. 21:2265-2268 (1980)
	38	REESE, Colin B. et al., "The Protection of Thymine and Guanine Residues in Oligodeoxyribonucleotide Synthesis," J. Chem. Soc. Perkin Trans. 1, pages 1263-1271 (1984)
	39	Reexamination Certificate - Application No. 90/011,320, issued March 27, 2012 (Exhibit Number 1072 filed in Interferences 106008, 106007 on December 23, 2014)
	40	Reply to EPO Communication dated June 26, 2014 in European Application Serial No. 13160338, (University of Western Australia Exhibit 2145, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-4).
	41	Reply to EPO Communication dated October 21, 2014 in European Application Serial No. 12198517, (University of Western Australia Exhibit 2148, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-7).
	42	Reply to EPO Communication dated October 23, 2014 in European Application Serial No. 12198485, (University of Western Australia Exhibit 2147, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1-8).
	43	Response to Office Action and Amendments to the Claims for Application No. 13/550,210, 10 pages, dated May 12, 2014 (Exhibit Number 2064 filed in interferences 106008, 106013, 106007 on November 18, 2014)
	44	Rhodes et al., "BioMarin Bulks Up," BioCentury, pp. 6-8 (December, 2014), Exhibit Number 1193 filed in Interferences 106,007 and 106,008 on February 17, 2015.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

	45	RNA Isolation Using RNA-BEE, Pages 1, Exhibit Number 1175 filed in Interferences 106,007 and 106,008 on February 16, 2015.
	46	ROBERTS, Roland G. et al., "Exon Structure of the Human Dystrophin Gene," Genomics, Vol. 16:536-538 (1993)
	47	Roest et al., "Application of In Vitro Myo-Differentiation of Non-Muscle Cells to Enhance Gene Expression and Facilitate Analysis of Muscle Proteins," Neuromuscul. Disord., Vol. 6, No. 3, pp. 195-202 (May, 1996), Exhibit Number 1124 filed in interferences 106,007 and 106,008 on February 17, 2015.
	48	ROSSO, Mario G. et al., "An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for flanking sequence tag-based reverse genetics," Plant Molecular Biology, Vol. 53:247-259 (2003)
	49	Saito, T. et al., "First-in-Human Study of NS-065/NCNP-01; the Morpholino Based Antisense Oligonucleotide for Exon 53 Skipping in Duchenne Muscular Dystrophy," ASGCT meeting , May 13, 2015, Abstract [136] 1 page.
	50	Saito, T. et al., "First-in-Human Study of NS-065/NCNP-01; the Morpholino Based Antisense Oligonucleotide for Exon 53 Skipping in Duchenne Muscular Dystrophy," ASGCT meeting , May 13, 2015, pages 1-11.

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	15705172
Filing Date	2017-09-14
First Named Inventor	Stephen Donald WILTON
Art Unit	1674
Examiner Name	Not Yet Assigned
Attorney Docket Number	AVN-008CN41

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Amy E. Mandragouras, Esq./	Date (YYYY-MM-DD)	2017-09-22
Name/Print	Amy E. Mandragouras, Esq.	Registration Number	36,207

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	30440717
Application Number:	15705172
International Application Number:	
Confirmation Number:	2879
Title of Invention:	ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
First Named Inventor/Applicant Name:	Stephen Donald WILTON
Customer Number:	123147
Filer:	Amy E. Mandragouras/Anita Costa
Filer Authorized By:	Amy E. Mandragouras
Attorney Docket Number:	AVN-008CN41
Receipt Date:	22-SEP-2017
Filing Date:	
Time Stamp:	17:07:55
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Form (SB08)	SB2.pdf	1073046 355198baf2613bb93713595efb0eef494c92b579	no	13

Warnings:

Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
2	Information Disclosure Statement (IDS) Form (SB08)	SB3.pdf	1072448 67c7ad17e6a0dc9f1769e558f3d07e18d349b933	no	11
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
3	Information Disclosure Statement (IDS) Form (SB08)	SB4.pdf	1069919 dec520e5b3d927cc8e4cf64d911c496853b71a5c	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
4	Information Disclosure Statement (IDS) Form (SB08)	SB5.pdf	1069449 ba40313de315f4dec1f9a32110c65ec359076243	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
5	Information Disclosure Statement (IDS) Form (SB08)	SB10.pdf	1063176 c32eec39a978355c4f941c38025125cdf81b8ba6	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					

6	Information Disclosure Statement (IDS) Form (SB08)	SB11.pdf	1062822 4828a2a56988fdff90d09c2e9ab956f9df5620fb	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
7	Information Disclosure Statement (IDS) Form (SB08)	SB12.pdf	1062574 d7e40a65a345f3325bbc488276dd67300e46c13c	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
8	Information Disclosure Statement (IDS) Form (SB08)	SB13.pdf	1064319 6572b386755cb262b46428bd784fef13d70ba156	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
9	Other Reference-Patent/App/Search documents	11570691.pdf	824636 b1d71a5423cfcbdc747bca834f34371d79a441b4	no	20
Warnings:					
Information:					
10	Other Reference-Patent/App/Search documents	12605276.pdf	3052455 6b079d4e84963b993a6d8b0b85dd7bf5246a107e	no	77
Warnings:					
Information:					

11	Other Reference-Patent/App/Search documents	12837356.pdf	1125002 7d5447617e4bddfd2424e1403dd112bb53477bf6	no	27
Warnings:					
Information:					
12	Other Reference-Patent/App/Search documents	12837359.pdf	1720784 39f2b87208fbd32fd5dc8a05cf21c5f9c8793e7c	no	43
Warnings:					
Information:					
13	Other Reference-Patent/App/Search documents	12860078.pdf	330860 258ddd90a3313de714b6fdd0f97951bbb7b22421	no	5
Warnings:					
Information:					
14	Other Reference-Patent/App/Search documents	13168857.pdf	328406 1b77d7a519c9b4966ebf7331ae532f959fb320bc	no	9
Warnings:					
Information:					
15	Other Reference-Patent/App/Search documents	13168863.pdf	953673 75890e005398e8da1561538cd7f5edc5d4d26aff	no	23
Warnings:					
Information:					
16	Other Reference-Patent/App/Search documents	13270500.pdf	1518462 d4b14d0d1ce4e349ab743a0c3ab1daba78e57fcf	no	37
Warnings:					
Information:					
17	Other Reference-Patent/App/Search documents	13270531.pdf	661676 a34a8a8703fa12c091a1195daba43351c7bff0c0	no	18
Warnings:					
Information:					

18	Other Reference-Patent/App/Search documents	13270744.pdf	1198792 d9311801bf221c828547edf308cab084161ebf0d	no	28
Warnings:					
Information:					
19	Other Reference-Patent/App/Search documents	13270937.pdf	1201425 82d5399512674134bc8354b842dbf7cb1126bf17	no	30
Warnings:					
Information:					
20	Other Reference-Patent/App/Search documents	13270992.pdf	1429782 54349a132fa1bda28ef37405a23d6006b7ac2211	no	37
Warnings:					
Information:					
21	Other Reference-Patent/App/Search documents	13271080.pdf	1180426 c629f772d342b4fcee726c39e0a00921f647f0de	no	30
Warnings:					
Information:					
22	Other Reference-Patent/App/Search documents	13509331.pdf	620522 0a679286a4d1346b914b57539955f747269c8c3a	no	13
Warnings:					
Information:					
23	Other Reference-Patent/App/Search documents	13727415.pdf	341405 cf41e336c31931d38290ae5411453722cb40ba10	no	9
Warnings:					
Information:					
24	Other Reference-Patent/App/Search documents	13741150.pdf	1312837 56cfe4fcfce3533db328d5fa8b340bdd2114a0bc	no	26
Warnings:					
Information:					

25	Other Reference-Patent/App/Search documents	13826613.pdf	865675 ae217f3bca5ff1d7f5c751796c547132a5fe1792	no	19
Warnings:					
Information:					
26	Other Reference-Patent/App/Search documents	13826880.pdf	1289334 c090a0236018fbae6b5cf3ad0c020628ba2c6860	no	26
Warnings:					
Information:					
27	Other Reference-Patent/App/Search documents	13829545.pdf	391313 9644b3c4b1cb8009fdbfb1b8884260e3cc8fa1a6	no	10
Warnings:					
Information:					
28	Other Reference-Patent/App/Search documents	13830253.pdf	769195 1242fc1883343a669dafeeae08c8a3f885f7ec20	no	16
Warnings:					
Information:					
29	Other Reference-Patent/App/Search documents	13902376.pdf	1290892 2bbf2ddbc5cb8c89a2343f26803153eea0d14001	no	32
Warnings:					
Information:					
30	Other Reference-Patent/App/Search documents	13963578.pdf	403329 3402d75f53e3d4cac07805b91e3b53a992e0df43	no	10
Warnings:					
Information:					
31	Other Reference-Patent/App/Search documents	14086859.pdf	647296 c11ab966c5b0d9558867e77e9f02adefe10d7620	no	15
Warnings:					
Information:					

32	Other Reference-Patent/App/Search documents	14108137.pdf	849006 5b48582097de7e4dd0951dc9431cf45c9017ff61	no	18
Warnings:					
Information:					
33	Other Reference-Patent/App/Search documents	14178059.pdf	373078 51fd4e3376bcfce4152ebdd82c80ae43ef149b7b	no	8
Warnings:					
Information:					
34	Other Reference-Patent/App/Search documents	14213607.pdf	1153046 a5d85ac9c07d17a054ac70b0d7ee10d637779599	no	25
Warnings:					
Information:					
35	Other Reference-Patent/App/Search documents	14213629.pdf	917107 ebdce12777edce60358255530c44892d0e812630	no	23
Warnings:					
Information:					
36	Other Reference-Patent/App/Search documents	14213641.pdf	5407199 e3e4a1984127ea855fd2b947c1e3b8e68ee1502b9	no	125
Warnings:					
Information:					
37	Other Reference-Patent/App/Search documents	14214480.pdf	5531647 47769b062d112ad0a371db38486bd858b917f7ec	no	129
Warnings:					
Information:					
38	Other Reference-Patent/App/Search documents	14214567.pdf	947976 bcc4df502112e0e4fb29c60d2df807d82b10b702	no	21
Warnings:					
Information:					

39	Other Reference-Patent/App/Search documents	14223634.pdf	346568 d2ad35987905441de8b67a24adaac5c6f274a20f	no	9
Warnings:					
Information:					
40	Other Reference-Patent/App/Search documents	14273318.pdf	1069737 19250769e0a95a5359c4bb08b99e392fd92ee5d7	no	27
Warnings:					
Information:					
41	Other Reference-Patent/App/Search documents	14273379.pdf	779288 d1bee3a17b36cf262546affd5511f529a7f60ea8	no	17
Warnings:					
Information:					
42	Other Reference-Patent/App/Search documents	14316603.pdf	895109 d45947c6797378a6b1d11b20e3ac2a95fb80a96d	no	21
Warnings:					
Information:					
43	Other Reference-Patent/App/Search documents	14316609.pdf	1048531 44030b7a819393f479c49efa9e8b01ea2665aedd	no	23
Warnings:					
Information:					
44	Other Reference-Patent/App/Search documents	14317952.pdf	706351 463631f0235c23f3a173d5744266a0e5faaf5655	no	14
Warnings:					
Information:					
45	Other Reference-Patent/App/Search documents	14523610.pdf	1213794 b225eac5cfbebf4a1536faf87bcb61f5d2570153	no	30
Warnings:					
Information:					

46	Other Reference-Patent/App/Search documents	14740097.pdf	917075 0989f8e4794f9e7a0ae034ce1ab616471673 78a3	no	19
Warnings:					
Information:					
47	Other Reference-Patent/App/Search documents	14743856.pdf	320959 71b8543c73fef28cc3085fc6622449de71f27 7dc	no	9
Warnings:					
Information:					
48	Other Reference-Patent/App/Search documents	14776533.pdf	846911 8bddf6142074e45a53bbb5dd05c2afc8d63 5c22d	no	21
Warnings:					
Information:					
49	Other Reference-Patent/App/Search documents	14852090.pdf	954681 c549f53d97cb070417db369d7bc58f9e730 eeda0	no	18
Warnings:					
Information:					
50	Other Reference-Patent/App/Search documents	14852149.pdf	361683 757eee3cd8596e225527cbaec402c34f1cb5 6649	no	6
Warnings:					
Information:					
51	Other Reference-Patent/App/Search documents	14852257.pdf	749921 44d935fd370e4f76d918d9d599634b53611 b345a	no	11
Warnings:					
Information:					
52	Other Reference-Patent/App/Search documents	14852264.pdf	816621 c048541fdf6765ca96797c2bf12dcc04b831f dd2	no	17
Warnings:					
Information:					

53	Other Reference-Patent/App/Search documents	14857555.pdf	1169163 0a94c12f5b3cf7bc09416e8ab245c525fb760cd1	no	12
Warnings:					
Information:					
54	Information Disclosure Statement (IDS) Form (SB08)	IDSTRANS.pdf	50276 13a3bdfb712873269000ce5571df1d4f77db5354	no	8
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
55	Information Disclosure Statement (IDS) Form (SB08)	SB6.pdf	1089106 199adb629310f6e9470334515f86536ab3836165	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
56	Information Disclosure Statement (IDS) Form (SB08)	SB8.pdf	1070179 d1cecba9ee54521a53c75ac10079b8920ed80df8	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
57	Information Disclosure Statement (IDS) Form (SB08)	SB9.pdf	1082063 2266dc70cc1a16858c72d12c6964c64eb87988ad	no	8
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					

58	Information Disclosure Statement (IDS) Form (SB08)	SB14.pdf	1089326 1a7b1bb58e7ccb0ac8675a762dfe4863952e4bac	no	8

Warnings:

Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

59	Information Disclosure Statement (IDS) Form (SB08)	SB1.pdf	1243016 5578a6b8352de49781eab64a3543a16fc876130a	no	32

Warnings:

Information:

60	Information Disclosure Statement (IDS) Form (SB08)	SB7.pdf	1102078 876c1d3a049c64e4d8f3c7b1e4fdb52f33a24895	no	8

Warnings:

Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

Total Files Size (in bytes):	66097425

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
15/705,172	09/14/2017	1674	730	AVN-008CN41	2	2

CONFIRMATION NO. 2879

123147
Nelson Mullins Riley & Scarborough LLP/Sarepta
One Post Office Square
Boston, MA 02109

FILING RECEIPT

OC000000094308384

Date Mailed: 09/26/2017

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Stephen Donald WILTON, Applecross, AUSTRALIA;
Sue FLETCHER, Bayswater, AUSTRALIA;
Graham MCCLOREY, Bayswater, AUSTRALIA;

Applicant(s)

The University of Western Australia, Crawley, AUSTRALIA;

Power of Attorney: The patent practitioners associated with Customer Number 123147

Domestic Priority data as claimed by applicant

This application is a CON of 15/274,772 09/23/2016
which is a CON of 14/740,097 06/15/2015 PAT 9605262
which is a CON of 13/741,150 01/14/2013 ABN
which is a CON of 13/168,857 06/24/2011 ABN
which is a CON of 12/837,359 07/15/2010 PAT 8232384
which is a CON of 11/570,691 01/15/2008 PAT 7807816
which is a 371 of PCT/AU2005/000943 06/28/2005

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.)
AUSTRALIA 2004903474 06/28/2004 No Access Code Provided

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 09/25/2017
The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 15/705,172**
Projected Publication Date: 01/04/2018
Non-Publication Request: No
Early Publication Request: No
** **SMALL ENTITY** **
Title

ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF

Preliminary Class

536

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific

countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop

technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.